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STUDIES ON
HETEROCYCLES OF
MEDICINAL INTEREST
SYNOPSIS
Studies on heterocycles...
1
“STUDIES ON HETEROCYCLES OF  MEDICINAL INTEREST”
The work incorporated in the thesis with the ti t le STUDIES ON
HETEROCYCLES OF  MEDICINAL INTEREST included investigations
pertaining to dihydropyrimidine and their derivatives have been described as under.
PART - I   :  STUDIES ON DIHYDROPYRIMIDINONES
PART - II :   STUDIES ON DIHYDROPYRIMIDINTHIONES
PART - I  :  STUDIES ON DIHYDROPYRIMIDINONES
Dihydropyrimidinone and their derivatives represent one of the most active
class of compounds possessing a wide spectrum of bilogogical activities such as
anti inf lammatory,  ant iviral ,  ant ibacter ial ,  ant i tumor,  calcium channel
blokers,antihypertenvsive agent and anticancer drugs. Many of their derivatives are
pharmacologically important as a1a adrenoceptor selective antagonists. In bening
prostatic  hyperplasia(BPH) which is a urological disorder in the aging male
population.
Several recently isolated marine alkaloids with interesting biological
activities also contain the dihydropyrimidinone nucleous.Most notably among these
are the batzelladines alkaloids. They inhibit the binding of HIV gp-120 to CD4 cells
and therefore are potential leads for AIDS therapy.
Recently the dihydropyrimidinones have been imolicated in the catabolism
of pyrimidine base.Their nucleosides and nucleotides play an important role as
antivirus and anticancer agents and they act as a fungicide to inhibit ergosterol
biosynthesis by inhibiting the P-450 enzyme.
In order to develope better medicinally important compounds, it was
considered of interest to synthesize some new dihydropyrimidinone derivatives shown
as under.
Studies on heterocycles...
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SECTION-I  : Synthesis and biological screening of 6-Methyl-N-(4-methyl
phenyl)-4-aryl-3,4-dihydropyrimidin-2(1H)-one-5-carboxamides.
 Dihydropyrimidinones of Type (I) have been synthesized by the
condensation of N-(4-methylphenyl)-3-oxobutanamide,urea and aryl aldehydes.
SECTION-II  : Synthesis and biological screening of Ethyl-6-(4-methoxy
phenyl)-4-aryl-3,4-dihydropyrimidin-2(1H)-one-5-
carboxylates.
The 6-(4-methoxyphenyl) dihydropyrimidinone carboxylates of Type (II) have
been synthesized by the condensation of ethyl-3-(4-methoxyphenyl)-3-
oxopropanoate,urea and aryl aldehydes.
NH
N
H
R
CH3
O
N
O
CH3
H
R = Aryl
Type (I)
NH
N
H
R
O
O
CH3
O
OCH3
R = Aryl
Type (II)
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SECTION-III : Synthesis and biological screening of N-(2,4-Dichlorophenyl)-
6-(4-methoxyphenyl)-4-aryl-3,4-dihydropyrimidin-2(1H)-one-5-
carboxamides.
The N-(2,4-dichlorophenyl)-6-(4-methoxyphenyl)dihydropyhimidinone
carboxamides of Type (III) have been synthesized by the condensation of N-(2,4-
dichlorophenyl)-3-(4-methoxyphenyl)-3-oxopropanamide,urea and aryl
aldehydes.
  SECTION-IV : Synthesis and biological screening of Ethyl-1-(3-chloro-4-
fluorophenyl)-4-aryl-6-methyl-3,4-dihydropyrimidin-2-one
-5-carboxylates.
The N-substituted dihydropyrimidinone carboxylates of Type (IV) have been
prepared by the condensation of ethylacetoacetate,N-(3-chloro-4-fluorophenyl)
urea and aryl aldehydes.
R = Aryl
Type (III)
NH
N
H
R
O
CH3
O
N
ClCl
O
H
NH
N
R
CH3 O
F
Cl
O
OCH3
R=Aryl
Type (IV)
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SECTION-V : Synthesis and biological screening of 1-(3-Chloro-4-fluoro
phenyl)-4-aryl-6-methyl-N-(4-methylphenyl)-3,4-dihydro
pyrimidin-2-one-5-carboxamides.
The N-substituted dihydropyrimidinone carboxymides of Type (V) have been
synthesized by the condensation of N-(4-methylphenyl)-3-oxobutanamide,N-(3-
chloro-4-fluorophenyl)urea and aryl aldehydes.
  SECTION-VI : Synthesis and biological screening of Ethyl-1-(3-chloro-4-fluoro
phenyl)-4-aryl-6-(4-methoxyphenyl)-3,4-dihydropyrimidin-2-
one-5-carboxylates.
NH
N
R
CH3
O
N
O
CH3
F
Cl
H
NH
N
R
O
F
Cl
O
CH3
O
OCH3
R = Aryl
Type (VI)
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N-Substituted dihydropyrimidinone carboxylates of Type (VI) have been syn-
thesized by the condensation of ethyl-3-(4-methoxyphenyl)-3-oxopropanoate, N-
(3-chloro-4-fluorophenyl)urea and aryl aldehydes.
PART - II :   STUDIES ON DIHYDROPYRIMIDINTHIONES
The ring system having a thio group occupy a unique position in medicinal
chemistry. This type of derivatives play an important role in biological processess
and in synthetic drugs. Dihydropyrimidinthione also occur very widely in nature. It is
one of   the component of nucleic acid, several analogs have been used as
compounds that interfere with the synthesis and functioning of nucleic acids, an
example is thiouracil which has been used in cancer treatment.
Dihydropyrimidinthione and its derivatives have been center of interest for
reaction for research chemist as they possess varied therapeutic activities such as
significant in vitro activity against unrelated DNA and RNA virues, antimalarial,
diuratic, antimicrobial, antilukemic and antineoplastic.
Keeping the association of dihydropyrimidinonthione derivatives with varid
biological activity, i t  was thought worthwhile to synthesize some new
dihydropyrimidinonthione derivatives as under.
SECTION-I  : Synthesis and biological screening of 6-Methyl-N-(4-methyl
phenyl)-4-aryl-3,4-dihydropyrimidin-2(1H)-thione-5-
carboxamides.
NH
N
H
R
CH3
O
N
S
CH3
H
R = Aryl
Type (VII)
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The synthesis of dihydropyrimidinthiones of Type (VII) have been
undertaken by the cyclocondensation of N-(4-methylphenyl)-3-oxobutanamide,
thiourea and aryl aldehydes.
SECTION-II  : Synthesis and biological screening of Ethyl-6-(4-methoxy
phenyl)-4-aryl-3,4-dihydropyrimidin-2(1H)-thione-5-
carboxylates.
The 6-(4-methoxyphenyl) dihydropyrimidinthione carboxylates of Type (VIII)
have been synthesized by the condensation of ethyl-3-(4-methoxyphenyl)-3-
oxopropanoate,thiourea and aryl aldehydes.
SECTION-III : Synthesis and biological screening of N-(2,4-Dichlorophenyl)-
6-(4-methoxyphenyl)-4-aryl- 3,4-dihydropyrimidin-2(1H)-
thione-5-carboxamides.
NH
N
H
R
S
O
CH3
O
OCH3
R = Aryl
Type (VIII)
R = Aryl
Type (IX)
NH
N
H
R
O
CH3
O
N
ClCl
S
H
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N-(2,4-Dichlorophenyl)-6-(4-methoxyphenyl) dihydropyhimidinthione
carboxamides of Type (IX) have been synthesized by the condensation of N-(2,4-
dichlorophenyl)-3-(4-methoxyphenyl)-3-oxopropanamide,thiourea and arylaldehydes.
SECTION-IV : Synthesis and biological screening of Ethyl-1-(3-chloro-4-fluoro
phenyl)-4-aryl-6-methyl- 3,4-dihydropyrimidin-2-thione-5-
carboxylates.
The N-substituted dihydropyrimidinthione carboxylates of Type (X) have been
synthesized by the condensation of ethylacetoacetate, N-(3-chloro-4-fluorophenyl)
thiourea and aryl aldehydes.
SECTION-V : Synthesis and biological screening of 1-(3-Chloro-4-fluoro
phenyl)-4-aryl-6-methyl-N-(4-methylphenyl)-3,4-dihydro
pyrimidin-2-thione-5-carboxamides.
NH
N
R
CH3 S
F
Cl
O
OCH3
R=Aryl
Type (X)
NH
N
R
CH3
O
N
S
CH3
F
Cl
H
R = Aryl
Type (XI)
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The N-substituted dihydropyrimidinthione carboxymides of Type (XI) have
been synthesized by the condensation of N-(4-methylphenyl)-3-oxobutanamide,N-
(3-chloro-4-fluorophenyl)thiourea and aryl aldehydes.
SECTION-VI : Synthesis and biological screening of Ethyl-1-(3-chloro-4-fluoro
phenyl)-4-aryl-6-(methoxyphenyl)-3,4-dihydropyrimidin-2-
thione-5-carboxylates.
The N-substituted dihydropyrimidinthione carboxylates of Type (XII) have
been synthesized by the condensation of ethyl-3-(4-methoxyphenyl)-3-
oxopropanoate,N-(3-chloro-4-fluorophenyl)thiourea and aryl aldehydes.
The constitution of all above products has been supported by elemental
analyses and spectral studies like IR, 1H NMR and Mass spectroscopy. The purity
of the compounds synthesized was checked by TLC.
NH
N
R
S
F
Cl
O
CH3
O
OCH3
R = Aryl
Type (XII)
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In vitro study on multiple biological activities:
[1] Selected compounds have been evaluated for their in vitro  biological assay
like antitubercular activity towards a strain of Mycobacterium tuberculosis
H37Rv  at a concentration of 6.25 mg/ml using Rifampin as a standard drug,
which have been tested by Tuberculosis Antimicrobial Acquisition
Co-ordinating Facility (TAACF), Alabama U.S.A.
[2] All the compounds have been evaluated for their antibacterial activity  towards
Gram positive and Gram negative bacterial strains and antifungal activity
towards Aspergillus niger at a concentration 40 mg/ml. The biological
activities of the  synthesized compounds have been compared with
standard drugs.
PART -  I
STUDIES ON
DIHYDROPYRIMIDINONES
Studies on heterocycles...
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GENERAL INTRODUCTION
The chemistry of the heterocyclic compounds is as logical as that of aliphatic or
aromatic compounds. This study is of great interest both from the theoretical as well as
practical stand point. A heterocyclic compound is one which possesses acyclic structure
with at least two different kinds of atoms in the ring. The most common type, contain
largely carbon atom, nitrogen, oxygen and sulphur are the most common heteroatoms,
but many other elements, including even bromine, chlorine can also serve. The hetero-
cyclic compounds containing the less common atoms have been subject to much inves-
tigation in recent years.
The variety of heterocyclic compounds is enormous, their chemistry is complex
and synthesizing them requires great skill. Among large number of heterocycles found in
nature nitrogen heterocycles are most abundant than those containing oxygen of sulphur
owing to their wide distribution in nucleic acid instance and involvement in almost every
physiological process of plants and animals.
Heterocyclic systems are encountered in many groups of organic compounds
possessing great applicability in industry as well as in our life in various ways i. e. most
of the sugars and their derivatives, including vitamin C, for instance, exist largely in the
form of five membered (Furanosied str.) or six membered (Pyranoised str.) ring containing
one oxygen atom. Most members of the vitamin B group possess heterocyclic rings
containing nitrogen, one examples is vitamin B6 (Pyridoxine), which is a derivative of
the pyridine essential in amino acid metabolism. Many other examples of the importance
of heterocyclic compounds in biological systems can be given.
Natural products containing heterocyclic compounds such as alkaloids and
glycosides have been used since old age, as remedial agents. Febrifagl alkaloid from
ancient Chinese drug, Chang Shan, reserpine from Indian rouwopifia, Curen alkaloid
from arrow poison, codenine,  j-tropine and strychnine are all examples of heterocyclic
compounds. Many antibiotics including penicillin, cephalosporin, norfloxacin,
Studies on heterocycles...
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streptomycin etc. also contain heterocyclic ring systems. Majority of the large number
of drugs being introduced in pharmacopeias in recent years are heterocyclic compounds.
Many veterinary products like pyrantel and morantel are the drug of choice as
broad spectrum anthelmintics. The herbicides atrazine and simazine are well known
example of heterocyclic agrochemicals. Plant pigments such as indigo, hemoglobin and
anthiocyanins, chlorophyll has contributed much colour chemistry and many other
heterocyclic colouring matters are in use since prehistoric times. The heterocyclic
tetraselena fulvalene was the first ionic molecular crystal to demonstrate superconductivity.
Heterocyclic compounds are obtainable by the following methods.
(a) Isolation from natural sources, i.e. alkaloids, amino acids, indigo dyes etc.
(b) Degradation of natural products i.e. acridine, furfural, indol, pyridine, quinoline,
thiophene etc.
(c) Synthesis: Synthesis methods for obtaining heterocyclic compounds may be
divided into ring closer reactions, addition reaction and replacement reaction.
Cyclisation is usually accomplished by elimination of some small molecules
such as water or ammonia from chain of suitable length.
Heterocyclic compounds have a great applicability as drugs because,
(i) They have a specific chemical reactivity.
(ii) They resemble essential metabolism and can provide false synthons in
biosynthetic process.
The current interest  in the creation of large, searchable libraries of organic
compounds has captured an imagination of organic chemists and the drug discovery
community. Efforts in numerous laboratories focused on the introduction of chemical
diversity have been recently reviewed and pharmacologically interesting compounds have
been identified for libraries of widely different compositions.
Studies on heterocycles...
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Research in the field of pharmaceutical has its most important task in the
development of new and better drugs and their successful introduction into clinical
practice. Central to these efforts, accordingly stand the search for pharmaceutical
substances and preparation which are new and original. In addition to these objectives
the searching for drug which exhibit a clear advantage over a drug already known. Such
advantages may be qualitative or quantitative improvement in activity, the absence of
undesirable side effect, a lower toxicity, improved stability of decreased cost.
It is important at the outset to note that drug discovery is not an unambiguous
term in the pharmaceutical R & D world. For example, it can be defined using either
programmatic or organizational approaches (or both), with several options on each
category. Hence, it is important first to understand this variability and to adopt a specific
definition for the purpose of this discussion.
The contribution of organic chemistry to be development of scientific medicine in
the 19th century mainly from acyclic and carbocyclic compounds, although the pyrazoline
antipyrin (I) was introduced as an antipyretic and analgesic in 1984 and the first barbiturate
baritone (veranol) (II) in 1903. Guttmann treated, malaria with methylene blue in 1891,
with slight success, and in 1912 he introduced acriflavine as trypancide, it has proved to
be more valuable as an antiseptic. Phenazopyridini (pyridium) (III) was introduced for
the same purpose in 1926, and although it is relatively ineffective it has continued to be
used since it has some analgesic action.
N
N
CH3
Ph
O
NHNH
O
OO
Et Et
N NH2
N
N
Ph
(I) (II) (III)
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AIMS AND OBJECTIVES
In the pharmaceutical field, these has always been and will continue to be a need
for new and novel chemical inhibition of biological fraction. Our efforts are focused on
the introduction of chemical diversity in the molecular framework in order to synthesizing
pharmacologically interesting compounds of widely different composition.
During the course of our research work, looking to the application of heterocyclic
compounds, several entities have been designed, generated and characterized using
spectral studies. The details are as under.
1. To generate several biologically active moieties such as dihydropyrimidinones,
dihydropyrimidinthiones,dihydropyrimidinone C-5 amides, dihydro pyrimidin
thione C-5 amides and N-1 substituted derivatives
2. To characterise these products for structure elucidation using various
spec t roscop ic  t echn iques  l ike  IR ,  PMR and  mass  spec t ra l  ana lys i s .
4. To evaluate these new products for better drug potential against different
strains of bacteria, fungi and antitubercular activity by Tuberculosis and
Antitumor Acquisation Coordinating Facility (TAACF) Southern Research
Institute, Alabama, U.S.A.
5. Purity of all compounds have been checked by thin layer chromatography.
In view of these facts, the research work presented in the theis are described in
following parts.
PART-I : STUDIES ON DIHYDROPYRIMIDINONES.
PART-II : STUDIES ON DIHYDROPYRIMIDINTHIONES.
Studies on heterocycles...
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INTRODUCTION
Pyrimidine is the most important member of all the diazines as this ring system
occurs widely in living organisms. Purines, uric acid, barbituric acid and anti-malarial
and anti-bacterial agents also contain the pyrimidine ring. The chemistry of pyrimidine
has been widely studied. Pyrimidine was first isolated by Gabriel and Colman in 1899.
Since pyrimidine is symmetrical about the line passing C-2 and C-5, the positions C-4
and C-6 are equivalent and so are N-1 and N-3. When a hydroxyl or amino group is
present at the 2-, 4-, of 6-, position than they are tautomeric with oxo and imino
respectively.
Despite the importance of dihydroazines (particularly those containing the 1,4-
dihydropyrimidine and dihydropyridine moiety
1
) for clarifying a wide range of theoretical,
medicinal and biological problems, the chemistry of this group of compounds is still
extremely spotty. 
2-6
 A deeper knowledge of the behavior of this class of compounds is,
therefore, desirable. From the theoretical  view point, it is essential to predict the structure,
binding properties, chemical reactivity, etc. of dihydro compounds from the number and
positioning of nitrogen atoms in the ring, as well as from the disposition of double bonds.
Such quantum mechanical calculations also enable an evaluation of the degree of aromatic
character in potential “homoaromatic” and “antiaromatic” isomers. Availability of novel
model compounds for verifying these predictions would open up new horizons in
theoretical heterocyclic chemistry, particularly in clarifying the structures leading to
spontaneous isomerization of a derivative or in verifying its redox properties.
From the biochemical point of view, dihydroazines are of intense interest because
of presence of this group at the active site of the “hydrogen transferring coenzyme”
NADH (reduced nicotinamide adenine dinucleotide). This nucleotide, a central participant
in metabolic processes in living organisms, participates in the reduction of various
unsaturated functionalities.
Studies on heterocycles...
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In the area of drug development, dihydroazines show great promise, particularly
since the 4-aryldihydropyridines exhibit powerful vasodilation activity via modifying the
calcium ion membrane channel.
7-11
  Additionally, dihydropyridines have been found to
actively transport medication across biological membranes.
12
Until recently, most of the information available on dihydroazines centered around
dihydropyridines, with very little data extending to the related dihydropyrimidines.
This lacuna has motivated our deep involvement in developing dihydropyrimidine
chemistry, particularly dihydropyrimidines containing no substituents on the ring nitrogen.
13
These molecules have long been considered unstable for oxidation, polymerization or
disproportionation reactions.
14
Figure (1)  depicts the five possible isomeric structures of dihydropyrimidines,
exhibiting different dispositions of the double bonds.
            1,2-                 1,4-                  1,6-                 2,5-                 4,5-
However, these structures are not easy to synthesize and, as a result,
most of the known dihydropyrimidines have either 1,2- (A) or the tautomeric 1,4- (B)
and 1,6- (C) geometry. On the basis of data available in the literature,
15,16
 the
dihydropyrimidines can be conveniently divided into two groups, within each of which
interconversion between isomers is possible under thermal conditions, namely, the 1,4-
(B), 1,6- (C), and 4,5- (E) compounds, and the 1,2- (A) and 2,5- (D) isomers. It is
worthwhile to note that, while thermal interconversion between the two groups is not
N
N
H
N
N
H
N
N
H
N
N
N
N
A B C D E
observed, photochemical rearrangement of 1,4-(or 1,6-)dihydropyrimidines to 1,2-
isomers has been reported.
17,18
Fig. 1
Studies on heterocycles...
16
It should be stressed that dihydroazines take part in various isomerization
processes, usually characterized by reversible or irreversible migrations within the
ring, the study of which is still in its infancy. Hydrogen migration, for example, is
classified either as rearrangement or tautomerism depending on its kinetic and
thermodynamic parameters; the former term is reserved for irreversible processes, while
the latter is used to describe fast reversible exchanges.
19
 A study of isomerization in
dihydropyrimidines provides an excellent opportunity for clarifying the factors regulating
these processes.
After successfully developing versatile synthetic techniques for obtaining a
variety of 1,4- and 1,6-dihydropyrimidines,
20-22
 as well as the observation of amidinic
tautomerism between the two,
23,24
 A. L. Weis et al.
15
 examining the possibility of
preparative synthesis of similarly N-unsubstituted 1,2-dihydro derivatives and studying
their properties. Particularly important goals of this study were the possible observation
of the formally allowed hydrogen shift,
23
 of “homoaromaticity”
25,26
 or of imine-enamine
tautomerism
27
 in these compounds, behaviors of which have been seen in other systems.
To date few reports on the formation of 1,2-dihydropyrimidines exist in the
literature, and in those cases where a product could be isolated and characterized,
the material was either an N-substituted derivative or else it contained geminal
disubstitution at position 2, situations that prevent the molecule from oxidizing to the
corresponding pyrimidine.
 Pyrimidine ring carrying various subtituents may be built up from two or three
aliphatic fragments by the principle synthesis or by a variety of other synthesis, which
are complimentary rather than alternative to it. A second type of synthesis is the
isomerisation or break down of another heterocycles such as an hydration of purine but
such roots are frequently used.
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SYNTHETIC ASPECT :-
(1) In 1893 Pietro Biginelli reported the first synthesis of dihydropyrimidines of
type- (1)  by a simple one-pot condensation reaction of ethyl acetoacetate,
benzaldehyde and urea under strongly acidic condition.
28,29
(2) Silica sulfuric acid efficiently catalyzes the three component Biginelli reaction
between an aldehyde, a b-cabonyl compound and urea in ethanol  to afford
the corresponding DHPMs in high yield.
30
  The catalyst is reusable and can
be applied several times without any decrease in the yield of the reaction.
(3) A novel one-pot condensation of an aldehyde, b-keto-ester and urea was
performed using iodotrimethylsilane in acetonitrile for the first time at room
temperature affording DHPMs.
31
(4) Some Biginelli compounds were synthesized by using a photochemistry
method.  The Biginelli three component cyclocondensation reaction in THF
medium using a mixture of b-ketoester or b-diketone, aryl aldehyde and urea
under irradiation with a tungstan lamp light gave DHPM-2-(1H)-ones.
32
(5) Substituted 3,4-DHPM-2(1H)-ones were prepared in high yield by Biginelli
condensation of an aldehyde, a dicarbonyl compound and urea in ethanol
using CoCl
2
.6H
2
O catalyst.
33
(6) DHPM-2(1H)-ones derivatives were effectively synthesized on the solution
polyethylene glycol (PEG) 4000,
34
 by heating or solvent-free Microwave
iradiation through the Biginelli three component cyclo condensation.
CH3 O
EtOOC
+ Ph CHO +
NH2 NH2
O
H
+ NH
N
H
Ph
OCH3
EtOOC
1
Studies on heterocycles...
18
(7) DHPM-2-(1H)-one was prepared from three component b-diketone, aldehyde
and urea coupling in ethanol catalyze by indium(III) tribromide(InBr
3
).
35,36
This modified one-pot Biginelli condensation provided not only simple
preparation but also this modified Biginelli reaction was oxygen-bridge.
(8) A ser ies  of  Big ine l l i  compounds  was  synthes ized  us ing  4-methyl
benzenesulfonic acid as a catalyst under, microwave irradiation.
37
 This simple
method provided dihydropyrimidin-2-one in 86-98% yield.
(9) A simple effective synthesis of DHPM-2-(1H)-one derivatives, using boric
acid as a catalyst from an aldehyde 1,3-dicarbonyl compound and urea in
glacial acetic acid is discribed.
38
  Compared with the classical Biginelli reaction
conditions, this new method has the advantage of excellent yield 86-97%
and the short reaction time (0.5-2hr).
(10) Montmorillonite clays have been widely used in organic synthesis due to their
ready availability, easy to set up and work up, mild experimental condition
and high yield and selectively.  Recently, Bigi
39
 reported that the Biginelli
reaction could be performed under solvent less conditions using KSF
montmorillonite.
While optimizing the reaction conditions of the Biginelli reaction Haixisa
Lin.
40
 found that treatment of b-ketoester, aryl aldehyde and urea with KSF
montmorillonite in methanol affords DHPMs in good to excellent  yield.
R2 O
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NH2 NH2
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(11) Subhas D. Bose et al.
41
 describe a general and practical route for the Biginelli
cyclocondensation reaction using cerium(III) chloride (CeCl
3
) heptahydrate
as catalyst.  Three different sets of reaction conditions were examined (I)
traditional ethanol reflux (ii) water reflux and (iii) solvent-free conditions.
This is a novel, one-pot combination that not only preserves the simplicity
of Biginelli’s one-pot reaction but also consistently produces excellent yields
of the DHPM-2(1H)-ones.
(12) Recently, Indium(III) chloride was emerged as a powerful Lewis catalyst
impar t ing  h igh  reg ion  and chemo se lec t iv i ty  in  var ious  chemica l
transformations. Ranu C.et al.
42
 describe a simple synthesis of DHPM-2-(1H)-
one derivatives, using indium(III) chloride (10 mol %) as a catalyst from an
aldehyde, b-dicarbonbyl compound and urea in THF.
(13) Novel one-pot Biginelli-type reaction was developed by Cnangtao Q. et al.
43
An aromatic or aliphatic aldehydes with b-dicarbonyl compounds and urea
heated in the presence of catalytic amount of (5 mol %)Yb(OTf)
3
 for 60-90
min. under solvent free condition afford the corresponding DHPM-2-(1H)
ones.The yield of classical Biginelli reaction can be increased from 20-50%
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O
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+
O
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NH2
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to 81-91% with reaction time shorted from 18-48 hr. to 60-90 min.  The
catalyst can be easily recovered and reused.
(14) Reddy Ch.et al.
44
 described practical rout for the Biginelli reaction using
Zirconium tetrachloride as a catalyst.  Three component condensation reaction
of an aromatic aldehyde, b -ketoester and urea in ethanol afford the
corresponding DHPM-2-(1H)-ones in high yield.
(15) A practical and green chemistry approach towards synthesis of DHPM-2-
(1H)-one without any solvent or catalyst.  This method was developed by
Ranu C. et al.
45
  Dihydropyrimidinone was prepared from three component
b-diketone, aldehyde and urea was heated under stirring at 100-105 0C afford
the corresponding DHPM-2-(1H)-one in high yield (82%) and purity (> 95%).
(16) Unprecedented catalytic three-component one-pot condensation reaction
described by Essa E. H. et al.
46
 They set new reaction condition that was
three Bilginelli components react in presence of 1.3 equivalent of BF3-OEt2,
(10 mol %) CuCl (10 mol%) AcOH in THF reflux for 18 hr. at 600C, afforded
corresponding DHPM-2(1H)-one.
R CHO
NH2 NH2
O
R1 R2
O O
+ +
Yb (OTf)3
100   C0
NH
N
H
OR2
O R
R1
R1 R2
O O
+ R3 CHO +
NH2 NH2
O NH
N
H
OR1
O R3
R2100 - 105   C0
1h
Studies on heterocycles...
21
(17) A novel one-pot condensation of an aldehyde, b-ketoester and urea was
performed using aceticacid as a solvent This method described by Flokers K.
et al.
47
 in 1932.
(18) DHPM-2(1H)-ones were prepared in high yield by Biginelli condensation of
an aldehyde, a dicarbonly compound and urea in ethanol using Mn(OAc)
3
 as
a catalyst.
48
(20) A simple effective synthesis of DHPM-2(1H)-one derivatives, using FeCl
3
 as
catalyst from an aldehyde, b-dicarbonyl compound and urea.
29
(21) K. Ramalinga et al.
49
 described a simple synthesis of DHPM-2(1H)-ones
derivatives using BiCl
3
 as a catalyst from an aldehyde, b-dicarbonyl compound
and urea.
(22) 3,4-DHPM-2(1H)-ones were prepared in high yield by Biginelli condensation
of an aldehyde, a dicarbonyl compound and urea in ethanol using LiClO
4
 as
catalyst.
50
(23) 3,4-DHPM-2(1H)-one derivatives were effectively synthesized on the solution
ionic liquid
51
 by  hea t ing  through the  Bigine l l i  th ree  component
cyclocondensation.
(24) Recently Kappe C. O.
52
 demonstrated that by using neat polyphosphate
ester(PPE) as reaction mediator coupled with microwave irradiation,
excellent yield of variously substituted DHPMs can be obtain.
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(25) Shingare M. S. et al.
53,54
 examined a simple but effective procedure for
Biginelli condensation reaction of an aldehyde, b-ketoester and urea using
catalytic amount of cadium chloride.
Many more new catalysts was tried on the Biginelli reaction for the yield
improvement and reduce the reaction time and also for generating libraries of new
molecules. There are many new references  on this topic as per Kappe C. O. they
suggested all the peoples are working in the field of yield improvement and publi-
cation point of view but some of them are devloping new molecules and test it
against various disease.
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55,56...73
55. NiCl 2.6H 20
56. P-TsOH, EtOH
57. CoCl 2.6H 2O-LaCl 3.6H 2O
58. Microwave(800W)
59. NiCl 2.6H 2O-HCl
60. Bi(OTf) 3.MeCN
61. NH 4Cl
62. Ferrihydrate silicarogel
63. Me3SiCl/NaI
64. Zn(OTf) 2
65. MgBr 2
66. Ag3PW12 O 14
67. KHSO 4
68. Con.HCl-ultrasound
69. CdCl 2,  MeCN
70. CuCl-LiCl
71. I 2CH 3CN
72. BiONO 3
73. P-TSA-grinding.
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Alternative Synthetic Strategies :-
Apart from the traditional Biginelli condensation, there are only a few other
synthetic methods available that lead to DHPMs. Since most of these protocols
lack the experimental and conceptual simplicity of the Biginelli one-pot, one-step
procedure, none of these have any significance today or can compete with the original
Biginelli MCR approach. One noticeable exception is the so-called “Atwal
modification” of the Biginelli reaction.
74-76
 Here, an enone of type (2) is first
condensed with a suitable protected urea or thiourea derivative (3) under almost
neutral conditions. Deprotection of the resulting 3,4-dihydropyrimidine (4) with
HCl or TFA/EtSH leads to the desired DHPMs (5) .
R2 O
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R1O H
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NH OR
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N
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NH
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2 3 4
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Multiple component reaction (MCR) : -
MCR is a reaction in which three or more reactants combine in a single
reaction event to yield a product that displays features of all inputs. Multicomponent
reactions (MCRs) are of increasing importance in organic and medicinal chemistry.
77-81
In times where a premium is put on speed, diversity, and efficiency in the drug
discovery process,
82,83
 MCR strategies offer significant advantages over conventional
linear-type syntheses. In an ideal case, the individual building blocks are commercially
Studies on heterocycles...
24
available or are easily synthesized and cover a broad range of structural variations.
MCRs can provide products with the diversity needed for the discovery of new lead
compounds or lead optimization employing combinatorial chemistry techniques.
78-82
The search and discovery for new MCRs on one hand,
84
 and the full exploitation of
already known multicomponent reactions on the other hand, is therefore of
considerable current interest. One such MCR that belongs in the latter category is
the venerable Biginelli dihydropyrimidine synthesis. In 1893, Italian chemist Pietro
Biginelli reported on the acid catalyzed cyclocondensation reaction of ethyl
acetoacetate, benzaldehyde and urea.
28
 The reaction was carried out by simply
heating a mixture of the three components dissolved in ethanol with a catalytic
amount of HCl at reflux temperature. The product of this novel one-pot, three-
component synthesis that precipitated on cooling of the reaction mixture was
identified correctly by Biginelli as 3,4-dihydropyrimidin-2(1H)-one (6) .
Apart from a series of publications by the late Karl Folkers
85,86
 in the mid
1930s, the Biginelli reaction  or  Biginelli condensation as it was hence forth called
was largely ignored in the early part of the 20th century. The synthetic potential of
this new heterocycle synthesis therefore remained unexplored for quite some time.
In the 1970s and 1980s, interest slowly increased, and the scope of the original
cyclocondensation reaction was gradually extended by variation of all three building
blocks allowing access to a large number of multifunctionalized dihydropyrimidines
of type (4) .
87
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Combinatorial Procedures :-
Combinatorial chemistry has rapidly become an important method for the
identification and optimization of lead compounds in drug discovery.
88-92
 In contrast
to traditional solution organic synthesis, which often requires time-consuming
purification procedures, combinatorial chemistry has been conducted almost
exclusively on solid polymer supports.
93,94
 Solid phase synthesis allows very simple
product isolation by filtration, but this advantage at the isolation stage can be a
detraction at the synthesis stage because reaction mixtures are inhomogeneous. To
overcome these drawbacks, reactions of polymers that are soluble under certain
conditions and insoluble under others have been introduced.
95,96
 It has also been
shown that imaginatively designed “traditional” solution reactions of organic
molecules can provide powerful tools in combinatorial synthesis.
97,103
The phase behavior of any reaction mixture, combinatorial or otherwise, is a
crucial feature that affects the ease of purification.
104
 To avoid chromatographic
purification, reactions should be planned such that the phase of the desired product
is different from the phases of all the other reaction components and undesired
products. The “fluorous phase”
105-112
  has recently been used to advantage in
traditional organic synthesis. The new techniques rely on the ability of a “fluorous”
(highly fluorinated) molecule to partition into the fluorous phase in a liquid-liquid
extraction between an organic solvent and a fluorous solvent.
113-116
Recently two type of combinatorial procedure for the Biginelli modification
were described.
[A] Solid phase modification of Biginelli condensation
[B] Flours phase modification of Biginelli condensation
[A] Solid phase modification of Biginelli condensation :-
Solid-phase modifications of MCRs are rapidly becoming one of the
corners tones  of  combinator ia l  synthes is  of  smal l -molecule  l ibrar ies .
78-80
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Multicomponent reactions such as the Biginelli condensation leading to heterocycles
are particularly useful for the creation of diverse chemical libraries, since the
combination of small-molecularweight building blocks in a single operation leads
to high combinatorial efficacy.
117,118
Since the experimental conditions for the traditional Biginelli reaction are
rather straightforward, small libraries of DHPMs are readily accessible by parallel
synthesis. Along these lines, Fre´chet and co-workers have described the generation
of a 140-member single-compound DHPM library by combination of 25 aldehydes,
6 ureas/thioureas, and 7 acetoacetates or acetoamides under standard reaction
conditions (EtOH/HCl).
120,121
 Likewise, it has been shown that small single-compound
DHPM libraries can be obtained in high yield by parallel synthesis employing the
solventless microwave-enhanced variation of the Biginelli reaction.
52
 The first actual
solid-phase modification of the Biginelli condensation was reported by Wipf and
Cunningham in 1995.
121
 In this sequence,  g-aminobutyric acid-derived urea was
attached to Wang resin using standard procedures.
The resulting polymer-bound urea (7) was condensed with excess b-ketoesters
and aromatic aldehydes in THF at 55 °C in the presence of a catalytic amount of
HCl to afford the corresponding immobilized DHPMs. Subsequent cleavage of
product from the resin by 50% trifluoroacetic acid  (TFA) provided DHPMs (8) in
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high yields and excellent purity. The key condensation step was further studied and
optimized with the aid of an automatic synthesizer demonstrating the solvent
dependence of this process.
122
An alternative protocol, where the acetoacetate building block is linked to
the solid support71. Thus, Biginelli condensation of Wang-bound acetoacetate (9)
with excess aldehydes and ureas in NMP/HCl provided the desired DHPMs on solid
support. Subsequent cleavage with 50% TFA furnished the free carboxylic acids
(10) in high overall yield.
123
[B] Flours phase modification of Biginelli condensation :-
In fluorous synthesis, the initial organic substrate is attached to a “fluorous
label”, which is of sufficient structure, size and fluorine content to render the attached
organic molecule fluorous.
116
 One or more reactions are then conducted, and the
fluorous components of the reaction are subsequently separated from all non-fluorous
(organic, inorganic, solid, volatile) components by an appropriate phase separation
technique. At the desired stage, the fluorous label is cleaved and the product is
rendered organic. Unlike solid phase techniques, fluorous synthesis allows the routine
use of standard reagents and reaction conditions. If solvents are well chosen, it is
R2 O
O
O
R1
+
O
Ar
H
NH
N OR2
O
O
R1
Ar
OH
O
NH2
NH O
O P
O
1. THF, HCI, 55
2. TFA, CH 2CI2
o
C
7 8
CH3 O
O
O
P
+
O
Ar
H
NH
N
H
OCH3
O
OH
Ar
1. NMP, H
2. TFA, CH 2CI2
NH2
NH2 O
+
9 10
Studies on heterocycles...
28
possible to have a homogeneous solution (that is, no phase separation) at the reaction
stage, but to readily induce phase separation by changing solvents at the purification
stage. Furthermore, “fluorous labels” are much more robust than most polymers
and linkers in current use for solid phase synthesis.
In an interesting variation of this protocol, the Biginelli reaction was also
adapted to fluorous-phase conditions by the Wipf and Curran groups.
124,125
 In fluorous
synthesis, an organic molecule is rendered soluble in fluorocarbon solvents by
attachment of a suitable fluorocarbon group (“fluorous tag”). Fluorocarbon solvents
are usually immiscible with organic solutions, and fluorous molecules partition out
of an organic phase and into a fluorous phase by standard liquid-liquid extraction.
At the desired stage of the synthesis, the fluorous label is cleaved and the product is
rendered “organic” again.
124
 In the fluorous Biginelli reaction, the fluorous urea
derivative (11) was prepared by at tachment of  a  sui table f luorous tag to
hydroxyethylurea. The fluorous urea (11) was then condensed with 10 equivelent
each of the corresponding acetoacetates and aldehydes in THF-benzotrifluoride
(BTF) containing HCl. After extraction of the fluorous DHPMs with fluorous solvent
(perfluorohexanes, FC-72), desilylation with tetrabutylammonium fluoride (TBAF)
followed by extractive purification provided the “organic” Biginelli products DHPMs
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.
 (12) in good overall yields. Considering the simple experimental techniques used
in this fluorous chemistry, automation should be feasible, thus allowing the
preparation of DHPM libraries.
125
By employing any of the solid-phase synthesis methods described above,
libraries of DHPMs can be generated in a relatively straightforward fashion. Biginelli
products are therefore contained in many commercially available small molecule
libraries or compound collections and have undoubtely been subjected to many high-
throughput screening (HTS) processes. However, all of these products would still
be racemic, and therefore screening will not address possible enantioselective effects
on molecular activity.
Enantiomerically Pure Dihydropyrimidines :-
Dihydropyrimidines of the Biginelli type are inherently asymmetric molecules,
and the influence of the absolute configuration at the stereogenic center at C4 on
biological activity is well documented.
126-131
 In SQ 32926 (11), for example, it is
exc lus ive ly  the  (R ) -enan t iomer  tha t  ca r r i e s  the  the rapeu t i ca l ly  des i red
antihypertensive effect.
126
 In other DHPM analogues, individual enantiomers were
demonstra ted  to  have opposing pharmacological  ac t iv i t ies .
131
 A c c e s s  t o
enantiomerically pure DHPMs is therefore of considerable interest and a prerequisite
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for the development of any drugs in this field.
In a recent the chromatographic enantioseparation of DHPM derivatives
accomplished by using a variety of commercially available chiral stationary phases
(CSPs) in normal- and reversed-phase analytical HPLC.
132
 Kappe C. O. and Co-
workers
133
 tested that out of 29 diverse racemic DHPM analogues, all but one was
separated on at least one of the eight CSPs with separation coefficients a  ranging
from 1.08 to 8.67.
In subsequent work, Frechet and co-workers reported the separation of
DHPMs on a standard Pirkle-type 3,5-dinitrobenzoylated CSP and the “reciprocal”
preparation of a p-basic DHPM-based CSP.
120,121
 Using a combinatorial approach
toward the recognition of chirality, out of a library of 108 racemic DHPMs, the 4-
(9-phenanthryl) derivative (13) was identified as a lead structure with a separation
coefficient of a =5.2 on a Pirkle-type CSP.
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The chiral separation of DHPMs by capillary electrophoresis (CE) using
quaternary ammonium-b-cyclodextrin as chiral buffer additive has also been
reported.
134
 A preparatively useful synthetic approach to the enantiomerically pure
antihypertensive agent (R )-SQ 32926 (19) was disclosed by Atwal et al.
126
Similar strategies have been used to obtain a number of pharmacologically
important DHPM derivatives in enantiomerically pure form.
126,127,129 Kappe C.O. et
al.
133
 developed a biocatalytic strategy toward the preparation of enantiopure (R )-
and (S)-SQ 32926 (19). The key step in the synthesis is the enzymatic resolution of
an N3-acetoxymethyl-activated dihydropyrimidone precursor by Thermomyces
lanuginosus lipase.
135
A critical point in every preparation of enantiomerically pure materials,
regardless of the method, is the assignment  of absolute configuration. For the DHPM
series, a simple protocol for absolute configuration assignment based on the
combination of enantioselective HPLC and circular dichroism (CD) spectroscopy
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has been developed.
136
By comparison of the characteristic CD spectra of individual DHPM
enantiomers with reference samples of known absolute configuration, the absolute
configuration of 4-aryl-DHPMs, such as monastrol (8),
137
 or SQ 32926 ( 5),
135
 could
be established. The enantiomers were obtained by semipreparative HPLC separation
of racemic DHPMs on chiral stationary phases.
135 The characteristic CD activity of
the enamide chromophor around 300 nm allows the assignment of absolute
configuration in this series of dihydropyrimidine derivatives.
136
As mentioned above, a generally applicable asymmetric synthesis of DHPMs
has not been reported yet. However, fused DHPMs of type (23) have recently been
obtained by Elliott et al.
138
 in diastereomerically pure form by asymmetric hetero-
Diels-Alder addition of chiral alkenyloxazolines (23) with isocyanates. Mechanistic
investigations suggest that the reaction proceeds in a stepwise manner (20 21
22  23).
139
 It remains to be seen if this strategy can be adapted toward a
more general synthesis of enantiopure DHPMs.
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Efforts to develop a practical asymmetric version of the Biginelli reaction
itself have failed so far. While chiral acetoacetates, e.g., (-)-menthyl acetoacetate,
show no diastereoselectivity at all,
140
 chiral aldehydes derived from carbohydrates
apparently can induce chirality at C4 of the pyrimidine ring.
141
Natural Product Synthesis
Over the last 10 years, a variety of structurally novel and complex guanidine
alkaloids have been isolated from marine sources, such as the Caribbean sponges
Ptilocaulis spiculifer or Batzella sp.
142 Among these are the batzelladine alkaloids
A-I  (24), ptilomycalin A (25), and the alkaloids crambescidin A, 800, and 816.
142
 A
closely related alkaloid, 13,14,15-isocrambescidin 800 (26) was subsequently isolated
from the Mediterranean sponge Crambe crambe.
142
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Although several strategies to assemble the tricyclic or pentacyclic cores of
these guanidinium alkaloids have been realized, one of the most efficient protocols
relies on an intramolecular Biginelli condensation as the key step. In fact, the
“tethered Biginelli strategy” developed by Overman and co-workers has so far proven
to be the only method that has allowed the enantioselective total synthesis of alkaloids
in this family.
143-149
When typical Knoevenagel conditions (morpholinium acetate) were employed,
cis stereoselection  was observed ( syn-28). In contrast, when the condensation was
carried out in the presence of polyphosphate ester (PPE),
150
 trans stereoselection
was observed (anty-29).
143
 The tricyclic guanidine syn-(31) was obtained in 82%
isolated yield and is identical with the methanolysis product of the naturally occurring
batzelladine B.
151
Similar strategies based on enantioselective Biginelli reactions were employed
in the total synthesis of batzelladine D (24),
145 ptilomycalin A (25),
146,149
 13,14,15-
isocrambescidin 800 ( 26),
147,148
 13,14,15-isocrambescidin 657,
148
 crambescidin 657,
149
and crambescidin 800.
149
In the context of an enantioselective total synthesis of the highly potent
neurotoxin saxitoxin (32b), the Kishi group has developed a novel trimolecular
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cycl iza t ion  reac t ion  tha t  i s  somewhat  reminiscent  of  the  Big ine l l i
condensation.
152,153,154
From the mechanistic point of view, an ureidocrotonate species of type (36)
has been discussed as an intermediate in this trimolecular cyclization.
155
 It is
interesting to note that corresponding enamides have also been considered as
intermediates in the classical Biginelli reaction.
156,157
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MECHANISTIC STUDIES :
In 1893 Biginelli reported the first synthesis of dihydropyrimidines of type
(37) by a simple one-pot condensation reaction of ethyl acetoacetate, benzaldehyde,
and urea.
28
Despite the importance and current interest in dihydropyrimidines of type
(37), the mechanism of the classical three-component Biginelli condensation has
not been elucidated with certainty and remains disputed.
87
 Early work by Folkers
and Johnson suggested that N,N- benzylidenebisurea, i.e. the primary bimolecular
condensation product of benzaldehyde and urea, is the first intermediate in this
reaction.
158
 Later, Sweet and Fissekis have proposed a different mechanism
postulating that carbenium ion (38), produced by an acid-catalyzed aldol reaction
of benzaldehyde with ethyl acetoacetate, is the key intermediate and is formed in
the first and limiting step of the Biginelli reaction.
159
To decide which of the two fundamentally different mechanistic proposals is
correct Kappe C. O.
157,158
 carried out a detailed reinvestigation of the mechanism of
the Biginelli  condensation using 1H and 13C NMR spectroscopy to identify possible
intermediates. To be able to monitor all reactions by 1H and 13C NMR spectroscopy,
it is very likely that this three component condensation proceeds via one of the
three possible bimolecular reaction pathways from the urea/aldehyde/acetoacetate
system.
CH3 O
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O H NH2
NH2 O
NH
N
H
O
O
CH3
EtO
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The “carbenium ion mechanism” was proposed by Sweet and Fissekis,
159
 who
investigated the reaction in 1973 and suggested that an acid-catalyzed aldol
condensation is the first and limiting step of the Biginelli condensation. It was
proposed that under acid catalysis benzaldehyde  and ethyl acetoacetate would react
in an aldol-type fashion to produce the corresponding aldol, which dehydrates in
the presence of acid to the resonance-stabilized carbenium ion (38).
159,161
Interception of cation (38) by urea or N-methylurea then produces ureides
(39), which ultimately cyclize to the Biginelli products (40).
159
 The main argument
for the proposed mechanism made by the authors
159
 relates to the fact that acid-
catalyzed treatment of independently prepared enone (41) with N-methylurea also
produced pyrimidine in moderate yield.
159
According to Sweet and Fissekis, protonation of enone (41) regenerates the
carbenium ion intermediate (38),
161
 which then can react with urea or N-methylurea.
It was also considered important that in the reaction of enone (41) with N-methylurea
only the N1-methyl derivative (40b) was produced and not the N3-substituted
isomer,which corresponds to the regiochemical outcome observed in the three
component Biginelli  reaction of ethyl acetoacetate,  benzaldehyde, and N -
methylurea.
87,162
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The so-called “ureidocrotonate mechanism” was already considered by
Folkers and Johnson
158
 but was ruled out as a mechanistic pathway since the
bimolecular condensation product of ethyl acetoacetate and urea, i.e. ureidocrotonate
(42a),
164
 was shown to rapidly hydrolyze under the typical Biginelli reaction
conditions (EtOH, HCl).
158
 Since the fact that ureidocrotonate (42a) is sensitive to
hydrolysis does not exclude this intermediate for the Biginelli reaction. The
independently prepared
164-166
  enamides (42a,b) were shown to rapidly hydrolize in
CD
3
OH when catalyt ic  amounts  of  acid (and water)  were present  While
ureidocrotonates (42a,b) can be prepared from diketones and substitued urea under
strictly anhydrous conditions, i.e. by allowing a mixture of diketone and substituted
urea to react in a desiccator over concentrated H
2
SO
4
 for several days,
164-166
 it is
evident that under Biginelli reaction conditions the equilibrium is far on the
acetoacetate/urea side.
Another argument against the involvment of an ureidocrotonate intermediate
relates to the fact that N-methylurea reacts with ethyl acetoacetate to furnish
exclusively regioisomer (42b) bearing the N-methyl substituent at the terminal amino
group .
165,166
 The  format ion  of  a  Bigine l l i  d ihydropyr imidine  in  a  5  +  1
cyclocondensation manner from (42b) and benzaldehyde would be expected to lead
to the N3-substituted Biginelli product (43b) ,
167
 which is observed neither in the
three component Biginelli reaction
87,159,162
  nor from the reaction of ureide (42b)
with benzaldehyde under Biginelli conditions.
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Finally, Kappe C. O. considered the original mechanistic proposal made by
Folkers and Johnson,
158
 who suggested that the first step in the three-component
Biginelli condensation is the reaction of benzaldehyde with urea. When benzaldehyde
and urea  were reacted under typical Biginelli conditions (CH
3
OH/HCl) at room
temperature, the anticipated condensation product bisureide (44a)
168-170
 started to
precipitate from the solution within 15-20 min. Bisureide (44a) was also formed
when equimolar amounts of the two components were employed, and the analogous
condensation product (44b)
171,172
 was produced when N-methylurea was used instead
of urea.
However, when these reactions were carried out in the presence of ethyl
acetoacetate under identical reaction conditions, bisureides (44a,b) were not formed,
but dihydropyrimidines (40a,b) started to precipitate slowly from the reaction
mixture within 1-2 hr. (complete conversion took 2-3 days).
 The addition of ureas to benzaldehyde  leads to N-(1-hydroxybenzyl)-ureas
of type (45) via standard nucleophilic addition. Although this is likely to be an
equilibrium reaction, “hemiaminals” (45) are expected to undergo rapid dehydration
in the presence of acid to a carbenium ion which may be formulated as a highly
Ph CHO
OH
N
H O
N H
R
Ph
H
+
-H2O
H
N
+
H O
N H
R
Ph
  
H
+
O
N N
H
Ph
N
H
O
N
R
H
H
R
N
Ph
EtOOC
CH3 O
H
O
NH
R
-H2O
NH
N
Ph
OCH3
EtOOC
R
48a; R = H
48b; R = Me
47a; R = H
47b; R = Me
-H
+
sub. urea
sub. urea
44a; R = H
44b; R = Me
45 46
Studies on heterocycles...
40
reactive N-acyliminium species, i.e. (46) . In the absence of the 1,3-dicarbonyl
compound a second equivalent of urea is added to furnish bisureides (44a,b) which
due to their low solubility
168-172
 precipitate from the reaction mixture. However, if
ethyl acetoacetate is present in the reaction medium, iminium ion (46) is intercepted
by the 1,3-dicarbonyl compound, possibly through its enol tautomer, to furnish
intermediates (47a,b) which then cyclize to the Biginelli compounds (48a,b) .
Monitoring the formation of bisureides (44a,b) from aldehyde and urea by 1H NMR
(CD
3
OH, HCl) did not allow the observation of any intermediates, e.g. (45), in this
process. The first addition step  is the rate-determining (slow) step and that both
the subsequent acid-catalyzed dehydration (45 46) and the addition of a second
equivalent of urea to the iminium ion (46 44) are fast steps, therefore not
allowing (45) to accumulate.
Finally the original mechanistic proposal put forward by Folkers and Johnson
in 1933,
158
 involving an aldehyde-urea condensation product as key intermediate in
the Biginelli condensation is essentially correct. The first step in this mechanism
evidently involves the acid-catalyzed formation of an N-acyliminium ion precursor
of type (46) from an aldehyde and urea component. In the case of amides and
carbamates, this reaction pathway is well-established,
173,174
 and at least one example
exists for ureas.
175,176
 The second step can be regarded as an addition of a p-
nucleophile, i.e. the enol tautomer of acetoacetate to the electrondeficient N -
acyliminium species (46). Additions of p-nucleophiles to iminium species are very
well-known and have proven to be valuable synthetic transformations in target-
oriented synthesis.
173,174
 Importantly, several examples of this type of reaction
involving 1,3-dicarbonyl compounds and urea-derived N-acyliminium ions yielding
dihydropyrimidines of type (37) are reported in the literature,
175,176
 providing
additional support for this mechanism.
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THERAPEUTIC IMPORTANCE  :-
Calcium ion plays a vital role in a large number of cellular processes, including
excitation-contraction and  stimulus-secretion.
177,179
 The regulation  of the intracellular
concentration of this ion makes possible the control of such Ca2+-dependent processes.
One means of accomplishing this is by the use of agents known as calcium channel
antagonists, which inhibit the movement of calcium through certain membrane
channel.
178,180,181
In recent years interest has also focused on aza-analogs such as dihydropyrimidines
of type (50) which show a very similar pharmacological profile to classical
dihydropyridine calcium channel modulators.
182-188  Over the past few years several lead-
compounds were developed ( i.e. SQ 32,926)
127,185,186
  that are superior in potency and
duration of antihypertensive activity to classical dihydropyridine drugs, and compare
favorable with second-generation analogs such as amlodipine and  nicardipine .
127,185
These inherently asymmetric DHPM derivatives are not only very potent calcium channel
modulators, but also have been studied extensively to expand the existing structure-
activity relationships and to get further insight into molecular interactions at the receptor
level.
182-188
DHP calcium channel antagonists (e.g. 49, nifedipine) are flexible molecules, in
which the C4-aryl moiety and the C3/C5 ester substituents can rotate, and the
conformation of the 1,4-dihydropyridine ring can change.
189  Despite many studies on
         49                         50, SQ 32926                              51
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the structure-activity relationships for DHPs and DHPMs with respect to calcium channel
antagonist-agonist modulation, there still remains debate on the exact stereochemical/
conformational requirements for activity.
187-191
 It was recently proposed that calcium
channel modulation (antagonist vs. agonist activity) is dependent on the absolute
configuration at C4, whereby the orientation of the 4-aryl group (R - versus S-enantiomer)
acts as a “molecular switch” between antagonist and agonist activity.
187,188
 In the receptor-
bound conformation the substituted aryl ring should be positioned axially, perpendicular
to, and bisecting the boat-like dihydropyridine ring, with the 4-aryl substituent (X)
prefering the synperiplanar (sp) orientation relative to C4-H (Fig. 1).
187,188
A cis-carbonyl ester orientation (with respect the C5=C6 bond) was also found
mandatory for calcium channel modulatory activity, whereas the right-hand side of the
dihydropyridine ring was proposed non-essential,
187,188
  providing a rationale for the
similar pharmacological profile observed for DHPs and DHPMs.
Kappe C. O. et al.
192
 synthesize the polycyclic DHPM derivative (51) that
represents a conformationally rigid analog of SQ 32,926
185
, “frozen” in the putative
bioactive conformation shown in Fig. 1. All structural changes on (50) are made on the
non-essential right hand side of the molecule, thereby not interfering with the receptor-
sensitive groups on the left-hand side.
Hidetsura Cho et al.
182
 synthesized the novel calcium antagonists 3-N-substituted-
3,4-dihydropyrimidines (52) and 3-N-substituted-dihydropyrimidin- 2(1H)-ones (53)
were regioselectively synthesized in good yields. Compounds  (54) and (55) exhibited
H
CH3
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R O
H
.. - - - -----
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hydrogen bond
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(essential)
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Fig-1
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not only more potent and longer lasting vasodilative action but also a hypotensive activity
with slow onset as compared with dihydropyridines. Moreover, some dihydropyrimidines
(56) ,   (54), and (55) were weaker in blocking atrioventricular conduction in anesthetized
open-chest dogs and less toxic than the dihydropyridines.
Atwal K. S. et al.
185
 described that in order to explain the potent
antihypertensive activity of the modestly active (ICw = 3.2 pM) dihydropyrimidine calcium
channel blocker (57) , they carried out drug metabolism studies in the rat and found (5)
is metabolized to compounds (58-62). Two of the metabolites, (58)  (ICw = 16 nM) and
(59) (ICw = 12 nM), were found to be responsible for the antihypertensive activity of
compound (57) . Potential metabolism of (58) into (59)  in vivo. Structure-activity studies
aimed at identifying additional aryl-substituted analogues of (59) led to (63g,j,p)  with
comparable potential in vivo, though these compounds were less potent than (59) in
vitro .
The results demonstrate that the active R-(-)-enantiomer (64a) of (59) is both
more potent and longer acting than nifedipine  as an antihypertensive agent in the SHR.
The in vivo potency and duration of (64a) is comparable to the long-acting
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dihydropyridine amlodipine.
The pioneering discovery of the angiotensin  converting enzyme (ACE) inhibitor
captopril as an antihpertensive agtent,
193
 the renin-angiotensin system has  beccome an
imprtent target for further drug  discovery.
194-196
 Due  to the commercial sucess of ACE
inhibitors, a large effort in medicinal chemistry has cotinued to focus on further
manipulation of  this system. Renin inhibitors
197
 and angiotensin II (AII) antagonists
198
have enjoyed considerable popularity among pharmaceutical scientists. However, the
use of both these classes agents as potential cardiovascular drugs  had  been hampered
by their peptidic nature, usually responsible for poor oral bioavailability and limited half-life.
Efforts of Atwal  K. S. et al.
199
 in this area have resulted  in the discovery of
dihydropyrimidines (65) and (66a,b) as plotent AII receptor antagonists
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Dhanapalan N. et al.
200  prepared dihydropyrimidinones such as compound (67)
exhibited high binding affinity and subtype selectivity for the cloned human a1a receptor.
Systematic modifications of (67) led to identification of highly potent and subtype-selective
compounds such as (+)-(68) and (+)-(69) , with high binding affinity (K1 ) 0.2 nM) for
a 1a receptor and greater than 1500-fold selectivity over a 1b and a 1d adrenoceptors.
The compounds were found to be functional antagonists in human, rat and dog prostate
tissues. Compound (+)-(69) exhibited excellent selectively to inhibit intraurethral pressure
(IUP) as compared to lowering diastolic blood pressure (DBP) in mongrel dogs
(Kb(DBP)/Kb(IUP) )= 40) suggesting uroselectivity for a 1a-selective compounds.
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T. G. Muralidhar et al.
201
 have synthesized several DHPM-one analogues among
this (+)-(70) and  (+)-(71)  give excellent selectivity (>880-fold) over a 1b and a 1d also
showed good selectivity over several other recombinant human G-protein coupled
receptors. These compounds showed good functional potency in isolated human prostate
tissues, with Kbs comparable to their in vitro a 1a binding data. In addition, compound
(+)-(70) also exhibited good uroselectivity (DBP Kb/ IUP Kb > 20-fold) in the in vivo
experiments in dogs.
Bharat L. et al.
202
 identify that compound (+)-(72) was a lead compound with a
binding and functional profile comparable to that of (+)-(71) . The putative  metabolite
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2-carboxamidophenylpiperazine has negligible affinity for the m-opioid receptor.
James C. et al.
203
 explores 4-aryldihydropyrimidinones attached to an
aminopropyl-4-arylpiperidine via a C-5 amide as selective a 1a receptor subtype
antagonists. In receptor binding assays, these types of compounds generally display K1
values for the a 1a receptor subtype <1 nM while being greater than 100-fold selective
versus the a 1b and a 1d receptor subtypes. Many of these compounds were also
evaluated in vivo and found to be more potent than terazosin in both a rat model of
prostate tone and a dog model of intra-urethral pressure without significantly affecting
blood pressure. While many of the compounds tested displayed poor pharmacokinetics,
compound (73) was found to have adequate bioavailability (>20%) and half-life (>6 h)
in both rats and dogs. Due to its selectivity for the a 1a over the a1b and a 1d receptors
as well as its favorable pharmacokinetic profile, (73) has the potential to relieve the
symptoms of BPH without eliciting effects on the cardiovascular system.
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Several recently isolated marine alkaloids with  interesting biologicalactivities
alos contain dihydropyrimidinone nucleous. Frederick C. et  al.
204
   desccribed that a
novel class of polyguanidine alkaloids isolated from the red Caribbean sponge Batzella
sp.
205,206
 Nine members of this group have now been identified by Smith-Kline Beecham
scientists from a program searching for modulators of protein-protein interactions. The
most complex batzelladine alkaloids, exemplified by batzelladine A(74) have two
polycyclic guanidine units, while batzelladines C, D, and E (75)  display a single tricyclic
guanidine moiety. A decahydro- or octahydro-5,6,8b-triazaacenaphthalene is the common
structural feature of the batzelladines, with these tricyclic units occurring with both the
syn and anti stereorelationships of the angular hydrogens that flank the pyrrolidine
nitrogen.
205-207
 Batzelladines A (74) and B are micromolar inhibitors of binding of the
HIV envelope protein gp-120 to the human CD4 receptor, while at similar concentrations
batzelladines F-I induce dissociation of the  protein kinase called p56lck from
CD4. 
205,206,208-214
Crambe crambe, a bright red encrusting sponge commonly found at shallow
depths along the rocky coast of the Mediterranean, is a rich source of structurally novel,
bioactive alkaloids.
215
 Rinehart and co-workers
216
 and later Braekman and his group,
217,218
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described a series of complex guanidinium alkaloids, including 13,14,15-isocrambescidin
800 (76), crambescidin 800 (77), crambescidin 844 (78) and crambescidin 816 (79) ,
from C. crambe . The related alkaloid, ptilomycalin A (80), was reported earlier by
Kashman, Kakisawa  and co-workers from sponges collected in the Caribbean and
Red Sea.
219-221
 Ptilomycalin A
219-222
 and several of the crambescidins
216-218
 show
substantial antitumor, antiviral and antifungal activities.
216-222
 As a result of its low
abundance, 13,14,15-isocrambescidin 800 has not been extensively screened, although
it is reported to be less cytotoxic to L-1210 cells than other crambescidins.
223
 The defining
structural feature of the crambescidin alkaloids is a pentacyclic guanidine linked by a
straight chain w-hydroxycarboxylic acid spacer to a spermidine or hydroxyspermidine
unit.
The 5,6-Dihydropyrimidine nucleosides have attracted attention as potential
antiviral and antitumor agents.
224,225
 Physiological dihydro nucleosides play an important
role in nucleic acid metabolism and appear frequently in the sequence of tRNA.
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dihydro analogues of thymidine (81c) can act as competitive substrates, to thymidine,
for thymidine kinase.
227,228
 5-Fluoro-6-hydroxy (or acetoxy)-5,6-dihydro-2’-deoxyuridine
diastereomers (81a,b) have been investigated as prodrugs to 5-fluoro-2’-deoxyuridine.
224
The 5,6-dihydro derivatives (81d–f)  of antiviral pyrimidine nucleosides as potential
prodrugs.
229-234 It was observed that the groups at C-5 and C-6 positions in the 5,6-
dihydro derivatives created a potentially interesting enhancement of lipophilicity with
respect to that of the parent nucleosides. It was also found that 5,6-dihydropyrimidine
nucleosides (81d–f)  serve as slow releasers (prodrugs) of the parent nucleosides in
vivo and were stable to glycosidic bond cleavage. These beneficial properties of 5,6-
dihydropyrimidine nucleosides (81d–f) encouraged us to further investigate 5,6-dihydro
derivatives of 2’-deoxyuridine and -thymidine to study their biological activity.
Rakesh Kumar
235
 synthesized, antiviral and cytotoxic activities of 5-bromo (or
chloro)-6-azido-5,6-dihydro-20-deoxyuridine (82,83) and thymidine (84,85) .
Compounds exhibited a broad spectrum of antiherpes activity against (HSV-1, HSV-2,
HCMV, and VZV).
Andrew L. H. et al.
236
 studied compounds belong to the HEPT (86) chemical
series.
237-241
 HEPT, or 1-[(2-hydroxyethoxy)-methyl]-6-(phenylthio)thymine, was one
of the earliest NNIs discovered but inhibits HIV-1 RT relatively weakly (IC50 ) 17
mM).
237-242
 MKC-442 (87), or 6-benzyl-1-(ethoxymethyl)- 5-isopropyluracil (I-EBU),
is a very potent inhibitor of HIV-1 RT (the IC50 being 2000-fold lower at 8 nM),
243,244
although only three relatively minor alterations have been made to the HEPT structure.
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The different spectrum of drug-resistance mutations between HEPT and MKC-442
parallels the variation in potency. A single mutation (Tyr188His) renders the virus
effectively resistant to HEPT.
245
Victor E. M.et al.
246 synthesized 5’-triphosphates of( 89) and (90) were evaluated
directly as reverse transcriptase(RT) inhibitors using both a recombinant enzyme and
enzyme obtained and purified directly from wild-type viruses. The results showed that
inhibition of  RT occurred only with the conformationally locked 2E (N)-methano-carba-
AZT 5’-triphosphate. This inhibition was equipotent to and kinetically indistinguishable
from that produced by AZT 5’-triphosphate. The antipodal 3E (S)-methano-carba-
AZT 5’-triphosphate, on the other hand, did not inhibit RT.
NH
N O
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New drug molecules under clinical study:
Recently many new molecules which are under study from phase-I to Phase-IV
clinical trials for different pharmacological action have shown that the basic characteris-
tic of morpholine to behave as hidden amine has attracted many medicinal chemists to
incorporate this feature in drug design. Some interesting compounds are as under.
Moreover one compounds
248
 is very active against Non-nucleoside inhibitor of
human hepatitis B virus (IC50 = 53 nM for reduction of HBV DNA in human hepatoma
HepG2.2.15 cells) with low cytotoxicity in uninfected cells (CC50 = 7 mcM). Compound
inhibited both viral DNA and viral cores in HepG2.2.15 cells and HBV-transfected cell
lines, whereas it did not affect the activity of endopolymerase and had no effect on other
DNA or RNA viruses. In vivo in a transgenic mouse model, oral doses of 3-100 mg/kg
b.i.d. or t.i.d. for up to 28 days dose-dependently.
decreased viral DNA in the liver and plasma with efficacy comparable to
lamivudine. However, unlike lamivudine, compound reduced cytoplasmic HBV core
antigen (HBcAg) in the liver of mice. Pharmacokinetic studies in mice showed rapid
absorption, 30% bioavailability and dose-proportional plasma levels.
N
H
N
CH3 CH3
O
O
CH3
N
H
NH
O CH3
O
CH3
NO2
Treatment of Hypertension
Calcium Channel Blokers
Calcium Channel Blokers
247
Company Name: Merck & Co.
91
92
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Name : Bay-41-4109
Anti Hepatitis B Virus Drugs
249
Bayer
.
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CH3
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CH3
CH3
calcium channel blocker
250
MAR-99
MAR-99
Leukotrine Antagonist
251
(Known anti-asthmatic agent, now reported to pos-
sess anti-ulcerative and gastric antisecretory activi-
ties, which inhibits hydrochloric acid-ethanol-,
stress- and indomethacin-induced ulcers in rat.
Calcium Channel Blockers
252
94
95
96
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Flucytosine
(fluorocytosine)
Antifungal Agent.
253
In vitro  susceptibility of Candida species
isolated from cancer patients against
some antifungal agents.
Primethamine
Antimalarial Agent.
254
Dipyridamole
Acute Myocardial Infection
Treatment of Antiplatlet Therapy.
Immunosuppressants
Oncolytic Drug
Antibacterial Drugs
39th Intersci Conf Antimicrob Agents
Chemother (Sept 26-29, San Francisco)
1999, Abst F1808
In vitro  activity of novel 6-anilinouracils
targeted to DNA polymerase III of Gram-
positive bacteria
TNK-6123
TNK-6123
Anti HIV Agent
Reverse Transcripase Inhibitors.
Non-nucleoside HIV-1 reverse tran-
scriptase inhibitor
Compound was active not only against
wild-type HIV-1 strains (IC50 = 3 nM
against IIIB and NL4-3 HIV-1 strains) but
also showed nanomolar
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With an intention of preparing the compounds possessing better therapeutic
activity, we have undertaken the synthesis of dihydropyrimidinones which have been
described in following sections
SECTION- I SYNTHESIS AND BIOLOGICAL SCREENING OF 6-
METHYL-N-(4-METHYLPHENYL)-4-ARYL-3,4-DIHYDRO
PYRIMIDIN-2(1H)-ONE-5-CARBOXAMIDES
SECTION-I I SYNTHESIS AND BIOLOGICAL SCREENING OF ETHYL-6-
(4-METHOXYPHENYL)-4-ARYL-3,4-DIHYDRO
PYRIMIDIN-2(1H)-ONE-5-CARBOXYLATES.
SECTION-III SYNTHESIS AND BIOLOGICAL SCREENING OF N-(2,4-DI
CHLOROPHENYL)-6-(4-METHOXYPHENYL)-4-ARYL-3,4-
DIHYDROPYRIMIDIN-2(1H)-ONE-5-CARBOXAMIDES.
SECTION-I V SYNTHESIS AND BIOLOGICAL SCREENING OF ETHYL-1-
(3-CHLORO-4-FLUOROPHENYL)-4-ARYL-6-METHYL-3,4-
DIHYDROPYRIMIDIN-2-ONE-5-CARBOXYLATES.
SECTION- V SYNTHESIS AND BIOLOGICAL SCREENING OF 1-(3-
CHLORO-4-FLUORO PHENYL)-4-ARYL-6-METHYL-N-(4-
METHYLPHENYL)-3,4-DIHYDROPYRIMIDIN-2-ONE-5-
CARBOXAMIDES.
SECTION-VI SYNTHESIS AND BIOLOGICAL SCREENING OF ETHYL-1-(3-
CHLORO-4-FLUOROPHENYL)-4-ARYL-6-(4-METHOXY PHE
NYL)-3,4-DIHYDROPYRIMIDIN-2-ONE-5-CARBOXYLATES.
Studies on heterocycles...
56
SECTION - I
SYNTHESIS AND BIOLOGICAL SCREENING OF 6-METHYL-N-(4-
METHYLPHENYL)-4-ARYL-3,4-DIHYDROPYRIMIDIN-2(1H)-ONE-5-
CARBOXAMIDES.
Much interest have been focused around dihydropyrimidinone derivatives
because of their wide variety of pharmacologidal properties and industrial
applications. In view of these findings and achieve to better drug potency, we have
synthesized 6-Methyl-N-(4-methylphenyl)-4-aryl-3,4-dihydropyrimidin-2(1H)-one-
5-carboxamides of Type (I) by the condensation of N-(4-methylphenyl)-3-
oxobutanamide with urea and aryl aldehydes.
The structure elucidation of synthesized compounds has been done on the
basis of elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay
like antibacterial activity towards gram positive and gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40µg/ml.
The biological activities of synthesized compounds were compared with standard
drugs.
Moreover, some selected compounds have been evaluated for their in vitro
biological assay towards a strain of Mycobacterium tuberculosis H37Rv at  a
concentration of 6.25 µg/ml using Rifampin as a standard drug which have been
tested at Tuberculosis Antimicrobial Acquisition Co-ordinating Facility (TAACF),
Alabama, U. S. A.
 Type(I)
 R=Aryl
NH
N
H
R
CH3
O
N
O
CH3
H
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CH3 NH2 +
CH3
O
O
EtO
Ethanol
CH3
O
N
CH3
O
H
O H
NH2
NH2 O
+
EthanolH
+
NH
N
H
CH3
O
N
O
CH3
H
Reaction Scheme
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ANTIMICROBIAL ACTIVITY
Method : Cup-Plate
257
Gram positive bacteria : Bacillus cocus
Bacillus subtillis
Gram negative bacteria : Proteus Vulgaris
Escherichia Coli
Fungi : Aspergillus niger
Concentration : 40µg/ml
Solvent : Dimethyl formamide
Standard drugs : Amoxicillin, Ampicillin, Benzyl penicillin,
Norfloxacin, Greseofulvin
The antimicrobial activity was compared with standard drug viz Amoxicillin,
Ampicillin, Benzyl penicillin, Norfloxacin, Greseofulvin and antifungal activity was
compared with viz Greseofulvin. The inhibition zones measured in mm.
ANTITUBERCULAR ACTIVITY
The antitubercular evaluation of the compounds was carried out at
Tuberculosis Antimicrobial Acquisition Co-ordinating Facility (TAACF) U.S.A.
Method : BACTEC 460 Radiometric system.
Bacteria : Mycobacterium Tuberculosis H37Rv
Concentration : 6.25 µg/ml.
Standard drug : Rifampin.
Studies on heterocycles...
59
Instrument : SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 4000-400 cm-1
(KBr disc.)
 Observed
Alkane C-H str. (asym.) 2922 2975-2950   255
-CH3 C-H str. (sym.) 2858 2880-2860     , ,
C-H i.p.def. (asym.) 1458 1470-1435     , ,
C-H o.o.p. def. (sym.) 1327 1390-1370     , ,
Aromatic C-H  str. 3030 3090-3030   256
C=C str. 1498 1540-1480     , ,
1402 1520-1480     , ,
C-H i.p. (def.) 1078 1125-1090     , ,
C-H o.o.p. (def) 808 835-810     , ,
Pyrimidine C=C str. 1595 1580-1520     , ,
   moity C-H str. 3062 3080-3030     , ,
C-H i.p. def. 1099 1125-1090     , ,
   Amine -NH str. 3404 3410-3380   255
-NH def. 1629 1635-1595     , ,
  Cabonyl -C=O str. 1710 1700-1725     , ,
   Amide          - C=O str. 1674 1690-1660          , ,
Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode
-10.0
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
110.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cm
 451.3
 488.0
 511.1
 569.0
 588.2
 621.0
 640.3
 663.5
 698.2
 742.5
 756.0 808.1
 898.8
 954.7
1022.2
1078.1
1099.3
1139.9
1190.0
1244.0
1271.0
1326.9
1402.2 1438.85 11517.9
1595.0
1629.774.11710.7
2424.4
2858.3
2922.0
3030.0
3062.7
3112.9
3276.8
3404.1
IR SPECTRAL STUDIES OF 6-METHYL-N-(4-METHYLPHENYL)-4-
PHENYL-3,4-DIHYDROPYRIMIDIN-2(1H)-ONE-5-CARBOXAMIDE.
NH
N
H
CH3
O
NH
O
CH3
Studies on heterocycles...
60
Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER Spectrometer
(300 MHz)
1 2.17 3 H singlet -CH3(Pyr.) -
2 2.23 3 H singlet Ar-CH3 -
3 5.37 1 H singlet Ar-Hc -
4 7.02-7.05 2 H doublet Ar-Ha,a’ Jaa ’=9.0
5 7.09-7.19 2 H doublet Ar-Hb,b’ Jbb ’=9.0
6 7.39 5 H multiplate Ar-H -
7 6.77 1 H singlet -NH(Amide)
8 6.93 1 H singlet -NH(Pyr.) -
Signal
  No.
Signal Position
    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
NH
N
H
CH3
O
NH
O
CH3
a
a'
b
b'
c
NMR SPECTRAL STUDIES OF 6-METHYL-N-(4-METHYLPHENYL)-4-
PHENYL-3,4-DIHYDROPYRIMIDIN-2(1H)-ONE-5-CARBOXAMIDE.
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF 6-METHYL-N-(4-
METHYLPHENYL)-4-ARYL-3,4-DIHYDROPYRIMIDIN-2(1H)-ONE-5-
CARBOXAMIDES.
(A) Synthesis of N-(4-methylphenyl)-3-oxobutanamide.
           A mixture of ethyl acetoacetate (1.30 gm, 0.01 mol) and p-toluidine (1.07gm,
0.01 mol) in ethanol was refluxed for 12 hrs. The resulting solution was poured on
to crushed ice. The separated solid was filtered and crystallized from ethanol, Yield
74%, m. p. 192
0
C, Anal.Calcd. for C11H13NO2 Calcd: C, 69.09; H, 6.85; N, 7.32%,
Found:  C, 69.07; H, 6.84; N, 7.30%.
(B) Synthesis of 6-Methyl-N-(4-methylphenyl)-4-phenyl-3,4-dihydro
pyrimidin-2(1H)-one-5-carboxamide.
A mixture of urea (0.60 gm, 0.01 mol), benzaldehyde (1.06 gm, 0.01 mol)
and  N-(4-methyl phenyl)-3-oxobutanmide (1.91 gm, 0.01 mol) in 15 ml of ethanol
containing few drops of concentrated hydrochloric acid was refluxed for 24 hrs.
The solution was allowed to stand for 12 hrs. at O
0
C.  The resulting solid mass
separated was filtered and, crystallized from dioxane. Yield 34%, m. p. 250
0
C,
Anal.Calcd. for C19H19N3O2 Calcd: C, 71.01; H, 5.96; N, 13.08%, Found:  C,
69.99; H, 5.94; N, 13.06%.
Similarly, other 6-Methyl-N-(4-methylphenyl)-4-aryl-3,4-dihydropyrimidin-
2(1H)-one-5-carboxamides were prepared. The physical data are recorded in
Table No. 1
(C) Biological screening of  6-Methyl-N-(4-methylphenyl)-4-aryl-3,4-
dihydropyrimidin-2(1H)-one-5-carboxamides.
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(a) Antibacterial activity
257
The purified products were screened for their antibacterial activity using
cup-plate agar diffusion method. The nutrient agar broth prepared by the usual
method was inoculated aseptically with 0.5 ml of 24 hrs. old subcultures of Bacillus
cocus, Bacillus subtillis, Proteus Vulgaris and Escherichia Coli in separate conical
flasks at 40-50 0C and mixed well by gentle shaking. About 25 ml content of the
flask was poured and evenly spreaded in a petridish (13 cm diameter) and allowed
to set for 2 hrs. The cups (10 mm diameter) were formed by the help of borer in
agar medium and filled with 0.04ml (40mg) solution of sample in DMF.The plates
were incubated at 37 0C for 24 hrs. and the control was also maintained with 0.04ml
of DMF in a similar manner and the zone of inhibition of the bacterial growth were
measured in millimeter and recorded in Graphical Chart No. 1
(b) Antifungal activity
257
A. niger was employed for testing antifungal activity using cup-plate
agardiffusion method. The culture was maintained on sabourauds agar slants
sterilized sabourauds agar medium was inoculated with 72 hrs. old 0.5ml suspension
of fungal spores in a separate flask. About 25ml of the inoculated medium was
evenly spreaded in a petridish (13cm diameter) and allowed to set for 2 hrs. the
cups (10mm diameter) were punched. The plates were incubated at 30 0C for 48
hrs. After the completion of incubation period, the zone of inhibition of growth in
the form of diameter in mm was measure. Along the test solution in each petridish
one cup was filled up with solvent, which acts as control. The zone of inhibition of
test solution  are recorded in Graphical Chart No. 1
(C)Antitubercular activity
The antitubercular evaluation of the compounds was carried out at
Tuberculosis Antimicrobial Acquisition and Co-ordination Facility (TAACF), USA.
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Primary screening of the compounds for the antitubercular activity have been
conducted at 6.25 mg/ml towards Mycobacterium tuberculosis H37Rv in BACTEC
12B using the BACTEC 460 radiometric system. The compounds demonstrating
atleast>90% inhibition in the primary screening has been tested at lower
concentration towards Mycobacterium tuberculosis H37Rv to determine the actual
minimum inhibitory concentration (MIC) in the BACTEC-460.
The antitubercular data have been compared with standard drug Rifampin at
6.25 mg/ml concentration and it showed 98% inhibition. The primary screening
method is described as under.
Antitubercular activity was determined using the BACTEC 460 system as
modi f i ed  be low.  S tock  so lu t ions  as  t e s t  compounds  were  p repared  in
dimethylsulfoxidie (DMSO) at 1 mg/ml and sterilized by passage through 0.22 mm
PFTE filters (Millex-FG, Millipore, Bedford MA). Fifty microliters was added to
4ml radiometric 7H12 broth (BACTEC 12B; Becton Dickinson Diagnostic
Instrument System, Sparks, MD ) to achieve a final concentration of 6.25 mg/ml.
Controls received 50 ml DMSO. Rifampin was solublized and diluted in DMSO
And added to bactec-12 broth to achieve a range of concentration for determination
of minimum inhibitory (MIC, lowest concentration inhibiting 99% of the inoculum).
M. Tuberculosis H37Rv (ATCC 27294; American type culture collection,
Rockville, MD) was culture at 37 0C on a rotary shaker in middlebrook 7H9 broth
(Difco Laboratories, Detroiet, MI) supplemented with 0.2 v/v glycerol and 0.05%
v/v Tween 80 until the culture turbidity achieved an optical density of 0.45-0.55 at
550nm. Bacteria were then pelleted by centrifugation, washed twice and resuspended
in one fifth the original volume in dulbecco’s phosephate buffered saline (PBS, Irvine
Scientific Santa, Nalgene, Rochester, NY) and aliquots were frozen at 80 0C.
Cultures were showed and an appropriate dilution performed such that a BACTEC-
12B vial inoculated with a 0.1 ml would reach a growth index (GI) of 999 in 5 days.
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One tenth of diluted inoculum was used to inoculate 4 ml fresh BACTEC
12B broth containing the compounds. An additional control vial was included which
received a further 1;100 diluted inoculam (as well as 50 ml DMSO) use an calculating
the MIC of Rifampin, respectively by establishing procedures.
Cultures were incubated in 37 0C and the GI determined daily until control
cultures achieved a GI og 999. Assays were usually completed in 5-8days. Percent
inhibition was defined as-1- (GI of test sample/GI of control) x 100. Minimum
inhibitory concentration of compound effecting a reduction in daily chang in GI,
which was less than that, observed with a 1:100 diluted control culture one day the
letter reached a GI of at least 30. The percentage of inhibition data of compounds
are recorded in Table No. 1
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1a 179637 ZP-1 C6H5 - Alamar H37R v >6.25 00
1b 179638 ZP-2 2-Cl-C6H4 - Alamar H37R v >6.25 00
1c 179639 ZP-3 3-Cl-C6H4 - Alamar H37R v >6.25 20
1d 179640 ZP-4 4-F-C6H4 - Alamar H37R v >6.25 00
1e 179641 ZP-5 2-NO2-C6H4 - Alamar H37R v >6.25 65
1f 179642 ZP-6 3-NO2-C6H4 - Alamar H37R v >6.25 00
1g 179643 ZP-7 C10H7 - Alamar H37R v >6.25 24
1h 179644 ZP-8 3-OCH3-C6H4 - Alamar H37R v >6.25 11
1i 179645 ZP-9 4-OCH3-C6H4 - Alamar H37R v >6.25 24
1j 179646 ZP-10 2,5-(OCH3)2-C6H3 - Alamar H37R v >6.25 07
1k 179647 ZP-11 2-OH-C6H4 - Alamar H37R v >6.25 13
1l 179648 ZP-12 3-C6H5 O-C6H4 - Alamar H37R v >6.25 32
   Sr.
   No.
Sample
   ID
 Corp
   ID
R Assay    Mtb
Strain
     %
Inhibi.
   MIC
 mg/ml
  TABLE  NO-1
TAACF, Southern Research Insitute
Primary Assay Summary Report
NAID/Southern Research Insitute/GWL Hansen’s Disease Centre/Colorado State
University proprietary Information
NH
N
H
CH3
O
N
O
CH3
R
H
ANTITUBERCULAR ACTIVITY OF 6-METHYL-N-(4-METHYLPHENYL)-
4-ARYL-3,4-DIHYDROPYRIMIDIN-2(1H)-ONE-5-CARBOXAMIDES.
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SECTION - II
SYNTHSIS AND BIOLOGICAL SCREENING OF ETHYL-6-(4-METHOXY
P H E N Y L ) - 4 - A R Y L - 3 , 4 - D I H Y D R O P Y R I M I D I N - 2 ( 1 H ) - O N E - 5 -
CARBOXYLATES.
Compounds containing pyrimidine ring are widely distributed in nature. Many
of these derivatives are reported to possess different biological activities. In view
of these reports, we have synthesized Ethyl-6-(4-methoxyphenyl)-4-aryl-3,4-
dihydropyrimidin-2(1H)-one-5-carboxylates of Type (II) by the condensation of
ethyl-3-(4-methoxyphenyl)-3-oxopropanoate,urea and aryl aldehydes.
The structure elucidation of synthesized compounds has been done on the
basis of elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay
like antibacterial activity towards gram positive and gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40µg/ml.
The biological activities of synthesized compounds were compared with standard
drugs.
Type(II)
NH
N
H
R
O
O
CH3
O
OCH3
R=Aryl
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 Observed
Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode
IR SPECTRAL STUDIES OF ETHYL-6-(4-METHOXYPHENYL)-4-(3-
NITROPHENYL)-3,4-DIHYDROPYRIMIDIN-2(1H)-ONE-CARBOXYLATE.
N H
N
H
O
O
CH3
O
OCH3
NO2
Alkane C-H str. (asym.) 2927 2975-2950 255
-CH3 C-H str. (sym.) 2856 2880-2860  , ,
C-H i.p.def. (asym.) 1463 1470-1435  , ,
C-H o.o.p. def. (sym.) 1340 1390-1370  , ,
Aromatic C-H  str. 3116 3090-3030 256
C=C str. 1464 1540-1480  , ,
1421 1520-1480  , ,
C-H i.p. (def.) 1091 1125-1090  , ,
C-H o.o.p. (def) 830 835-810  , ,
Pyrimidine C=C str. 1598 1580-1520  , ,
   moity C-H str. 3039 3080-3030  , ,
C-H i.p. def. 1045 1125-1090  , ,
   Amine -NH str. 3244 3410-3380 255
-NH def. 1647 1635-1595  , ,
  Cabonyl -C=O str. 1724 1700-1725  , ,
   Ester            - C=O str. 1701 1690-1660       , ,
0.0
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cm
 455.2
 497.6
 515.0
 565.1
 605.6
 661.5
 700.1
 758.0
 877.6
 956.6
1026.1
1091.6
1145.6
1182.3
1220.9
1271.0
1290.3
1313.4
1340.4
1367.4
1386.7
1421.4
1463.9
1598.9
1647.1
1701.1
1724.2
2856.4
2927.7
3039.6
3116.8
3244.0
Instrument : SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 4000-400 cm-1
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Signal
  No.
Signal Position
    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
1 1.23 3 H triplet -CH3 -
2 3.86 3 H singlet Ar-OCH3 -
3 3.94 2 H quatret -CH2 -
4 5.54 1 H singlet Ar-Hc -
5 6.82-6.85 2 H doublet Ar-Hb,b’ Jaa ’=9.0
6 7.44-7.69 5 H multiplet Ar-H
7 8.07-8.10 2 H doublet Ar-Ha,a’ Jbb ’=9.0
8 8.14 1 H singlet NH(Pyr.) -
NH
N
H
O
O
CH3
O
OCH 3
NO2
a
a'
b
b'
c
NMR SPECTRAL STUDIES OF ETHYL-6-(4-METHOXYPHENYL)-4-(3-
NITROPHENYL)-3,4-DIHYDROPYRIMIDIN-2(1H)-ONE-CARBOXYLATE.
Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER Spectrometer
(300 MHz)
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF ETHYL-6-(4-METHOXY
P H E N Y L ) - 4 - A R Y L - 3 , 4 - D I H Y D R O P Y R I M I D I N - 2 ( 1 H ) - O N E - 5 -
CARBOXYLATES.
(A) Synthesis of Ethyl-3-(4-methoxyphenyl)-3-oxopropanoate.
To a well stirred solution of liquid ammonia (30 ml), add minimum amount
of sodium to produced a blue colour with few crystals of ferric nitrate. When all the
sodium converted into sodium amide, p-metoxy acetophenone (15 gm, 0.1 mol) in
20 ml of diethyl ether was added over a period of five minutes. The reaction mixture
was placed on a steam bath until all the ammonia evaporated. Then add diethyl
carbonate (24.2 gm, 0.2 mol). The mixture was stirred and refluxed for 2 hrs. The
resulting solution was poured over crushed ice and neutralize with glacial acetic
acid. The ether phase was separated and was washed with sodium bicarbonate
solution. Distilledd the ether and liquid was separated, Yield-85% b.p.190-192
0
C,
Anal.Calcd. for C12H14O4 Calcd: C, 64.65; H, 6.35,  Found:  C, 6.62; H, 6.33,%.
(B) Synthesis of Ethyl-6-(4-methoxyphenyl)-4-(3-nitrophenyl)-3,4-dihydro
pyrimidin-2(1H)-one-carboxylate.
A mixture of urea (0.60 gm, 0.01 mol), m-nitrobenzaldehyde (1.51 gm, 0.01
mol) and ethyl-3-(4-methoxyphenyl)-3-oxopropanoate (2.22 gm, 0.01 mol) in 15
ml of ethanol containing few drops of concentrated hydrochloric acid was refluxed
for 24 hrs. The solution was allowed to stand for 12 hrs. at O
0
C and the resulting
solid mass separated was filtered and crystallized from dioxane.Yield 41%, m.p.301
0
C, Anal.Calcd. for C20H19N3O6 Calcd: C,60.45; H, 4.82; N, 10.57%, Found:  C,
60.43; H, 4.81; N, 10.54%.
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Similarly, other Ethyl-6-(4-methoxyphenyl)-4-aryl-3,4-dihydropyrimidin-
2(1H)-one-5-carboxylates  were prepared. The physical data are recorded in Table
No. 2
(C) Biological screening Ethyl-6-(4-methoxyphenyl)-4-aryl-3,4-dihydro-
pyrimidin-2(1H)-one-5-carboxylates.
Antimicrobial testing were carried out as described in Part-I Section-I(C).
The zones of inhibition of test solutions are recorded in Graphical Chart No.2
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SECTION - III
SYNTHESIS AND BIOLOGICAL SCREENING OF N-(2,4-
D I C H L O R O P H E N Y L ) - 6 - ( 4 - M E T H O X Y P H E N Y L ) - 4 - A RY L - 3 , 4 -
DIHYDROPYRIMIDIN-2(1H)-ONE-5-CARBOXAMIDES.
Dihydropyrimidinone have been repported to have various pharmacological
activities like antibacterial, antifungal, insecticidal etc. In order to achieving better
drug potency, we have synthesized dihydropyrimidinone derivatives of  type(III) by
the cyclocondensat ion of  N-(2,4-dichlorophenyl)-3-(4-methoxyphenyl)-3-
oxopropanamide,urea and aryl aldehydes.
The structure elucidation of synthesized compounds has been done on the
basis of elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay
like antibacterial activity towards gram positive and gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40µg/ml.
The biological activities of synthesized compounds were compared with standard
drugs.
Moreover, some selected compounds have been evaluated for their in vitro
biological assay towards a strain of Mycobacterium tuberculosis H37Rv at  a
concentration of 6.25 µg/ml using Rifampin as a standard drug which have been
tested at Tuberculosis Antimicrobial Acquisition Co-ordinating Facility (TAACF),
Alabama, U. S. A.
Type(III)
R=Aryl
NH
N
H
R
O
CH3
O
N
ClCl
O
H
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 Observed
Type     Ref.
        Reported
Frequency in cm-1 Vibration
IR SPECTRAL STUDIES OF N-(2,4-DICHLOROPHENYL)-6-(4-METH
OXYPHENYL)-4-PHENYL-3 ,4 -DIHYDROPYRIMIDIN-2(1H)-ONE-5-
CARBOXAMIDE.
NH
N
H
O
CH3
O
NH
ClCl
O
Alkane C-H str. (asym.) 2922 2975-2950 255
-CH3 C-H str. (sym.) 2842 2880-2860  , ,
C-H i.p.def. (asym.) 1450 1470-1435  , ,
C-H o.o.p. def. (sym.) 1348 1390-1370  , ,
Aromatic C-H  str. 3086 3090-3030 256
C=C str. 1483 1540-1480  , ,
C-H i.p. (def.) 1093 1125-1090  , ,
C-H o.o.p. (def) 806 835-810  , ,
Pyrimidine C=C str. 1510 1580-1520  , ,
   moity C-H str. 3006 3080-3030  , ,
C-H i.p. def. 1055 1125-1090  , ,
   Amine -NH str. 3408 3410-3380 255
-NH def. 1595 1635-1595  , ,
  Cabonyl -C=O str. 1728 1700-1725  , ,
   Amide           - C=O str. 1685 1690-1660       , ,
  Halide -C-CI str. 704 700-750  , ,
-10.0
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
110.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cm
 420.5
 457.1
 480.2
 513.0 547.7
 563.2
 596.0
 628.8
 669.3
 704.0
 732.9
 765.7
 806.2
 840.9
 854.4
 883.3
 908.4
 974.0
 997.1
1028.0
1055.0
1093.6
1172.6
1265.2
1286.4
1311.5
1348.1
1450.4
1483.2
1510.2
1595.0
1685.7
1728.1
2842.9
2922.0
3006.8
3085.9
3203.5
3354.0
3408.0
Mode
Instrument : SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 4000-400 cm-1
(KBr disc.)
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Signal
  No.
Signal Position
    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
1 3.92 3 H singlet Ar-OCH3 -
2 5.75 1 H singlet Ar-Hc -
3 7.00-7.03 2 H doublet Ar-Hb,b’ Jaa ’=9.0
4 7.29-7.46 8 H multiplet Ar-H -
5 7.59-7.62 2 H doublet Ar-Ha,a’ Jbb ’=9.0
6 9.15 1 H singlet -NH(Amide) -
NMR SPECTRAL STUDIES OF N-(2,4-DICHLOROPHENYL)- 6 - ( 4 - M E T H
OXYPHENYL)-4-PHENYL-3 ,4 -DIHYDROPYRIMIDIN-2(1H)-ONE-5-
CARBOXAMIDE.
NH
N
H
O
CH3
O
NH
ClCl
O
a
b
a'
b'
c
Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER Spectrometer
(300 MHz)
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF N - ( 2 , 4 -
D I C H L O R O P H E N Y L ) - 6 - ( 4 - M E T H O X Y P H E N Y L ) - 4 - A RY L - 3 , 4 -
DIHYDROPYRIMIDIN-2(1H)-ONE-5-CARBOXAMIDES.
(A) Synthesis of Ethyl-3-(4-methoxyphenyl)-3-oxopropanoate.
See Part-I, Section-II (A).
(B) Synthesis of N-(2,4-Dichlorophenyl)-3-(4-methoxyphenyl)-3-oxopropa-
namide.
A mixture of ethyl-3-(4-methoxyphenyl)-3-oxopropanoate (2.22 gm, 0.01
mol) and 2,4-dichloro aniline (1.62 gm, 0.01 mol) ) in ethanol was reflux for 10-12
hrs. The resulting solution was poured over crushed ice. The separated solid was
filtered and crystallized from ethanol, Yield 71%, m.p.267 0C, Anal.Calcd. for
C16H13Cl2NO3 Calcd: C, 56.32; H, 3.87; N, 4.14%, Found:  C, 56.30; H, 3.86; N,
4.13%.
(C) Synthesis of N-(2,4-Dichlorophenyl)-6-(4-methoxyphenyl)-4-phenyl-3,4-
dihydropyrimidin-2(1H)-one-5-carboxamide.
A mix tu re  o f  N- (2 ,4 -d ich lo ropheny l ) -3 - (4 -me thoxypheny l ) -3 -
oxopropanamide (3.38 gm, 0.01 mol), urea (0.60 gm, 0.01 mol) and benzaldehyde
(1.06 gm, 0.01 mol) in 15 ml of ethanol containing few drops of concentrated
hydrochloric acid was refluxed for 24 hrs. The solution was allowed to stand for 12
hrs.  at  O0C and the resulting solid mass separated was filtered and, crystallized
from dioxane. Yield 39%, m.p.227 0C, Anal.Calcd. for C24H19Cl2N3O3 Calcd: C,
61.55; H, 4.09; N, 8.97%, Found:  C, 61.53; H, 4.08; N, 8.96%
Similarly, other N-(2,4-Dichlorophenyl)-6-(4-methoxyphenyl)-4-aryl-3,4-
dihydropyrimidin-2(1H)-one-5-carboxamides were prepared. The physical data are
recorded in Table No.3
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(C) Biological screening of N-(2,4-Dichlorophenyl)-6-(4-methoxyphenyl)-4-
aryl-3,4-dihydropyrimidin-2(1H)-one-5-carboxamides.
Antimicrobial testing were carried out as described in Part-I Section-I(C).
The zones of inhibition of test solutions are recorded in Graphical Chart No.3
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3a 179663 ZP-27 C6H5 - Alamar H37R v >6.25 52
3b 179664 ZP-28 2-Cl-C6H4 - Alamar H37R v >6.25 00
3c 179665 ZP-29 3-Cl-C6H4 - Alamar H37R v >6.25 00
3d 179666 ZP-30 4-F-C6H4 - Alamar H37R v >6.25 12
3e 179667 ZP-31 2-NO2-C6H4 - Alamar H37R v >6.25 65
3f 179668 ZP-32 3-NO2-C6H4 - Alamar H37R v >6.25 45
3g 179669 ZP-33 4-CI-C6H4 - Alamar H37R v >6.25 47
3h 179670 ZP-34 3-OCH3-C6H4 - Alamar H37R v >6.25 00
3i 179671 ZP-35 4-OH-C6H4 - Alamar H37R v >6.25 00
3j 179672 ZP-36 2,5-(OCH3)2-C6H4 - Alamar H37R v >6.25 12
3k 179673 ZP-37 2-OH-C6H4 - Alamar H37R v >6.25 00
3l 179674 ZP-38 2-OH-4-OCH3-C6H3 -Alamar H37R v >6.25 25
  Sr.
  No.
Sample
   ID
 Corp
   ID
R Assay    Mtb
Strain
     %
Inhibi.
   MIC
 mg/ml
  TABLE  NO-3
TAACF, Southern Research Insitute
Primary Assay Summary Report
NAID/Southern Research Insitute/GWL Hansen’s Disease Centre/Colorado State
University proprietary Information
NH
N
H
O
N
O
Cl
R
H
Cl
O
CH3
ANTITUBERCULAR ACTIVITY OF N-(2,4-DICHLOROPHENYL)-6-(4-
METHOXYPHENYL)-4-ARYL-3,4-DIHYDROPYRIMIDIN-2(1H)-ONE-5-
CARBOXAMIDES.
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SECTION - IV
SYNTHESIS AND BIOLOGICAL SCREENING OF ETHYL-1-(3-CHLORO-
4-FLUOROPHENYL)-4-ARYL-6-METHYL-3,4-DIHYDROPYRIMIDIN-2-
ONE-5-CARBOXYLATES.
The broad spectrums of pharmacological properties have been demonstrate
by  the  d ihydropyr imid inone  nuc leus . Insp i red  by  these  f ac t s ,  nove l
dihydropyrimidinone derivatives of type(IV) have been synthesized by the
condensation of ethylacetoacetate,N-(3-chloro-4-fluorophenyl)urea  and aryl
aldehydes.
The structure elucidation of synthesized compounds has been done on the
basis of elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay
like antibacterial activity towards gram positive and gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40µg/ml.
The biological activities of synthesized compounds were compared with standard
drugs.
Type(IV)
R=Aryl
NH
N
R
CH3 O
F
Cl
O
OCH3
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 Observed
Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode
IR SPECTRAL STUDIES OF ETHYL-1-(3-CHLORO-4-FLUOROPHENYL)-4 -
( 3 - NITROPHENYL)-6-METHYL-3,4-DIHYDROPYRIMIDIN-2-ONE- 5 -
CARBOXYLATE.
NH
N
CH3
O
F
Cl
O
O
CH3
O2N
Alkane C-H str. (asym.) 2929 2975-2950 255
-CH3 C-H str. (sym.) 2841 2880-2860  , ,
C-H i.p.def. (asym.) 1440 1470-1435  , ,
C-H o.o.p. def. (sym.) 1346 1390-1370  , ,
Aromatic C-H  str. 3111 3090-3030 256
C=C str. 1460 1540-1480  , ,
C-H i.p. (def.) 1095 1125-1090  , ,
C-H o.o.p. (def) 823 835-810  , ,
Pyrimidine C=C str. 1595 1580-1520  , ,
   moity C-H str. 3074 3080-3030  , ,
C-H i.p. def. 1064 1125-1090  , ,
   Amine -NH str. 3438 3410-3380 255
-NH def. 1645 1635-1595  , ,
  Cabonyl -C=O str. 1730 1700-1725  , ,
  Ester                - C=O str 1701 1690-1660          , ,
  Halide -C-CI str. 742 700-750  , ,
0.0
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cm
 418.5
 464.8
 518.8
 584.4
 609.5
 632.6
 675.0
 717.5
 742.5
 771.5
 804.3
 823.5
 842.8
 906.5
 933.5
 981.7
1022.2
1064.6
1095.5
1112.9
1172.6
1218.9
1255.6
1290.3
1315.4
1346.2
1440.7
1460.0
1508.2
1531.4
1595.0
1645.21701.1
1730.0
2339.5
2360.7
2841.0
2929.7
2952.8
3074.3
3111.036.
3261.4
3438.8
Instrument : SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 4000-400 cm-1
(KBr disc.)
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Signal
  No.
Signal Position
    (dppm)
 Relative No.
  of protons
Multiplicity Inference
   J Value
    In Hz
NMR SPECTRAL STUDIES OF ETHYL-1-(3-CHLORO-4-FLUOROPHENYL)-
4- (3-NITROPHENYL)-6-METHYL-3,4-DIHYDROPYRIMIDIN-2-ONE
-5-CARBOXYLATE.
1 0.91 3 H triplet -CH3     -
2 2.10 3 H singlet Ar-CH3     -
3 4.07 2 H quatret -CH2     -
4 5.36 1 H singlet Ar-Hc     -
5 7.21-8.51 7 H multiplet Ar-H     -
6 10.04 1 H singlet NH(Pyr.)     -
NH
NCH3 O
F
Cl
O
OCH3
NO2
c
Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER Spectrometer
(300 MHz)
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF ETHYL-1-(3-CHLORO-
4-FLUOROPHENYL)-4-ARYL-6-METHYL-3,4-DIHYDROPYRIMIDIN-2-
ONE-5-CARBOXYLATES.
(A) Synthesis of N-(3-chloro-4-fluorophenyl)urea.
           A mixture of 3-chloro-4-fluoroaniline hydrochloride (18.1 gm, 0.1 mol) and
urea (24.0 gm, 0.4 mol) was placed in a 1-lit round-bottomed flask. To this mixture
were added 40 ml of water,1 ml of concentrated hydrochloric acid and 1 ml of
glacial acetic acid. The mixture was heated vigorously untill the entire contents of
the vessel suddenly set to a solid mass. The source of heat is immediately withdrawn
at this point. After cooling to room temperature, the product was broken up with
the addition of water, filtered and washed with cold water. Yield 58%, m.p.228
0
C ,
Anal.Calcd. for C7H6CIFN2O Calcd: C, 44.58; H, 3.21; N, 14.85%, Found:  C,
44.57; H, 3.19; N, 14.84%.
(B) Synthesis of Ethyl-1-(3-chloro-4-fluorophenyl)-4-(3-nitrophenyl)-6-
methyl-3,4-dihydropyrimidin-2-one-5-carboxylate.
A mixture of ethyl acetoacetate (1.30 gm, 0.01 mol), N-(3-chloro-4-
fluorophenyl)urea (1.88 gm, 0.01 mol) and m-nitrobenzaldehyde (1.51 gm, 0.01
mol) in 15 ml of ethanol containing few drops of concentrated hydrochloric acid
was refluxed for 24 hrs. The solution was allowed to stand for 12 hrs. at O
0
C. The
resulting solid mass separated was filtered and, crystallized from dioxane. Yield
51%, m.p.268
0
C, Anal.Calcd. for C20H17CIFN3O5 Calcd: C, 55.37; H, 3.95; N,
9.69%, Found:  C, 55.35; H, 3.94; N, 9.67%.
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Similarly, other Ethyl-1-(3-chloro-4-fluorophenyl)-4-aryl-6-methyl-3,4-
dihydropyrimidin-2-one-5-carboxylates were prepared. The physical data are
recorded in Table No.4
(C) Biological screening of  Ethyl-1-(3-chloro-4-fluorophenyl)-4-aryl-6-
methyl-3,4-dihydropyrimidin-2-one-5-carboxylates.
Antimicrobial testing were carried out as described in Part-I Section-I(C).
The zones of inhibition of test solutions are recorded in Graphical Chart No.4
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SECTION - V
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-(3-CHLORO-4-
FLUOROPHENYL)-4-ARYL-6-METHYL-N-(4-METHYLPHENYL)-3,4-
DIHYDROPYRIMIDIN-2-ONE-5-CARBOXAMIDES.
N1-substituted dihydropyrimidinone play vital role owing to their range of
biological and physiological activities.In the light of these biological activities and
variety of industrial applications,some new N1-substituted dihydropyrimidinone
derivatives of Type (V) have been synthesized by the condensation N - ( 4 -
methylphenyl)-3-oxobutanamide with N-(3-chloro-4-fluorophenyl)urea and aryl
aldehydes
The structure elucidation of synthesized compounds has been done on the
basis of elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay
like antibacterial activity towards gram positive and gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40µg/ml.
The biological activities of synthesized compounds were compared with standard
drugs.
Type(V)
R=Aryl
NH
N
R
CH3
O
N
O
CH3
F
Cl
H
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 Observed
Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode
IR SPECTRAL STUDIES OF 1-(3-CHLORO-4-FLUOROPHENYL)-4-( 3 -
N I T R O P H E N Y L ) - 6 - M E T H Y L - N - ( 4 - M E T H Y L P H E N Y L ) - 3 , 4 -
DIHYDRO PYRIMIDIN-2-ONE-5-CARBOXAMIDE.
Alkane C-H str. (asym.) 2923 2975-2950 255
-CH3 C-H str. (sym.) 2839 2880-2860  , ,
C-H i.p.def. (asym.) 1440 1470-1435  , ,
C-H o.o.p. def. (sym.) 1371 1390-1370  , ,
Aromatic C-H  str. 3062 3090-3030 256
C=C str. 1471 1540-1480  , ,
C-H i.p. (def.) 1083 1125-1090  , ,
C-H o.o.p. (def) 825 835-810  , ,
Pyrimidine C=C str. 1566 1580-1520  , ,
   moity C-H str. 3018 3080-3030  , ,
C-H i.p. def. 1153 1125-1090  , ,
   Amine -NH str. 3419 3410-3380 255
-NH def. 1647 1635-1595  , ,
  Cabonyl -C=O str. 1706 1700-1725  , ,
   Amide             - C=O str 1678 1690-1660         , ,
  Halide -C-CI str. 736 700-750  , ,
N
H
N
CH3
O
NH
O
F
Cl
CH3
NO2
0.0
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cm
 410.8
 447.5
 509.2
 594.0
 615.2
 646.1
 700.1
 736.8
 750.3
 763.8
 825.5
 844.8
 906.5
 927.7
 950.8
 989.4
1020.3
1083.9
1112.9
1153.4
1168.8
1203.5
1247.9
1299.9
1326.9
1371.3
1413.7
1440.7
1471.6
1506.3
1566.1
1595.0
1647.1
1676.0
1706.9
2341.4
2839.0
2923.9
3018.4
3062.7
3284.5
3419.6
Instrument : SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 4000-400 cm-1
(KBr disc.)
Studies on heterocycles...
100
Signal
  No.
Signal Position
    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
NH
NCH3
O
N
O
CH3
F
Cl
H
NO2
a
b
a'
b'
c
NMR SPECTRAL STUDIES OF 1-(3-CHLORO-4-FLUORPHENYL)-4-(3-
NITROPHENYL)-6-METHYL-N-(4-METHYLPHENYL)-3,4-DIHYDRO
PYRIMIDIN-2-ONE-5-CARBOXAMIDE.
1 2.25 3 H singlet -CH3(Pyr.) -
2 2.30 3 H singlet Ar-CH3 -
3 5.59 1 H singlet Ar-Hc -
4 7.01-7.04 2 H doublet Ar-Ha,a’ Jaa ’=9.0
5 7.08-7.35 7H          multiplate Ar-H -
6 7.55-7.58 2 H doublet Ar-Hb,b’ Jbb ’=9.0
7 9.86 1 H singlet -NH(Amide) -
8 9.97 1 H singlet -NH(Pyr.) -
Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER Spectrometer
(300 MHz)
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-(3-CHLORO-4-
FLUOROPHENYL)-4-ARYL-6-METHYL-N-(4-METHYLPHENYL)-3,4-
DIHYDROPYRIMIDIN-2-ONE-5-CARBOXAMIDES.
(A) Synthesis of N-(4-methylphenyl)-3-oxobutanamide.
See Part-I, Section-I (A).
(B) Synthesis of N-(3-chloro-4-fluorophenyl)urea.
See Part-I, Section-IV (A).
(C) Synthesis of 1-(3-Chloro-4-fluorophenyl)-4-(3-nitrophenyl)-6-methyl-N-
(4-methylphenyl)-3,4-dihydropyrimidin-2-one-5-carboxamide.
A mixture of N-(4-methyl phenyl)-3-oxobutanmide (1.91 gm, 0.01 mol), N-
(3-chloro-4-fluorophenyl)urea (1.88 gm, 0.01 mol) and m-nitrobenzaldehyde (1.51
gm, 0.01 mol) in 15 ml of ethanol containing few drops of concentrated hydrochloric
acid was refluxed for 24 hrs. The resulting solution was allowed to stand for 12 hrs.
at  O
0
C, thus the solid mass separated was filtered and crystallized from dioxane.
Yield 38%, m.p.305 
0
C, Anal.Calcd. for C25H20CIFN4O4 Calcd: C, 60.67; H, 4.07;
N, 11.32%, Found:  C, 60.66; H, 4.05; N, 11.31%.
Similarly, other 1-(3-Chloro-4-f luorophenyl)-4-aryl-6-methyl-N-(4-
methylphenyl)-3,4-dihydropyrimidin-2-one-5-carboxamides were prepared. The
physical data are recorded in Table No.5
(D) Biological screening of 1-(3-Chloro-4-fluorophenyl)-4-aryl-6-methyl-N-
(4-methylphenyl)-3,4-dihydropyrimidin-2-one-5-carboxamides.
Antimicrobial testing were carried out as described in Part-I Section-I(C).
The zones of inhibition of test solutions are recorded in Graphical Chart No.5
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SECTION - VI
SYNTHESIS AND BIOLOGICAL SCREENING OF ETHYL-1-(3-CHLORO-
4 - F L U O R O P H E N Y L ) - 4 - A R Y L - 6 - ( 4 - M E T H O X Y P H E N Y L ) - 3 , 4 -
DIHYDROPYRIMIDIN-2-ONE-5-CARBOXYLATES.
Dihydropyrimidinone derivatives represent one of the most classes of
compound having a wide spectrum of biological activities.With an aim to get better
therapeutic agent the dihydropyrimidinone derivatives of type (VI) have been
synthesized by the condensation of ethyl-3-(4-methoxyphenyl)-3-oxopropanoate,
N-(3-chloro-4-fluorophenyl)urea and aryl aldehydes.
The structure elucidation of synthesized compounds has been done on the
basis of elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay
like antibacterial activity towards gram positive and gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40µg/ml.
The biological activities of synthesized compounds were compared with standard
drugs.
NH
N
R
O
F
Cl
O
CH3
O
OCH3
Type(VI)
R=Aryl
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O H
NO2
NH2
NH O
Cl
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+
EthanolH
+
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N
O
O
Cl
F
NO2
EtO
O
CH3
O
CH3
O
O
EtO
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Studies on heterocycles...
107
 Observed
Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode
I R  S P E C T R A L  S T U D I E S  O F  E T H Y L - 1 - ( 3 - C H L O R O - 4 -
F L U O R O PHENYL)-4-( 3 - NITROPHENYL)-6-(4-METHOXYPHENYL)-
3,4-DIHYDROPYRIMIDIN-2-ONE-5-CARBOXYLATE.
N
H
N
O
F
Cl
O
CH3
O
O
CH3
NO2
Alkane C-H str. (asym.) 2956 2975-2950 255
-CH3 C-H str. (sym.) 2844 2880-2860  , ,
C-H i.p.def. (asym.) 1437 1470-1435  , ,
C-H o.o.p. def. (sym.) 1344 1390-1370  , ,
Aromatic C-H  str. 3035 3090-3030 256
C=C str. 1465 1540-1480  , ,
C-H i.p. (def.) 1118 1125-1090  , ,
C-H o.o.p. (def) 825 835-810  , ,
Pyrimidine C=C str. 1556 1580-1520  , ,
   moity C-H str. 3074 3080-3030  , ,
C-H i.p. def. 1172 1125-1090  , ,
   Amine -NH str. 3425 3410-3380 255
-NH def. 1608 1635-1595  , ,
  Cabonyl -C=O str. 1726 1700-1725  , ,
   Ester              - C=O str 1660 1690-1660         , ,
  Halide -C-CI str. 777 700-750  , ,
0.0
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cm
 418.5
 503.4
 569.0
 597.9
 640.3
 675.0
 748.3
 777.3
 825.5
 860.2
 885.3
 927.7
 964.3
1008.7
1029.9
1118.6
1172.6
1193.9
1267.11315.4
1344.3
1384.8
1436.9
1517.9
1556.4
1573.81608.5
1660.6
726.2
2524.6
2769.6
2844.8
2956.7
3035.7
3076.2
3425.3
3649.1
Instrument : SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 4000-400 cm-1
(KBr disc.)
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Signal
  No.
Signal Position
    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
NH
N O
F
Cl
O
CH3
O
OCH3
NO2
a
b
a'
b'
c
NMR SPECTRAL STUDIES OF ETHYL-1- (3 -CHLORO-4-FLUORO
P H E N Y L ) - 4 -( 3 - N I T R O P H E N Y L ) - 6 - ( 4 - M E T H O X Y P H E N Y L ) - 3 , 4 -
DIHYDROPYRIMIDIN-2-ONE-5-CARBOXYLATE.
1 1.23 3 H triplet -CH3 -
2 3.91 3 H singlet Ar-OCH3 -
3 4.16 2 H quatret -CH2 -
4 5.56 1 H singlet Ar-Hc -
5 6.99-7.02 2 H doublet Ar-Hb,b’ Jaa ’=9.0
6 7.21-8.33 7 H multiplet Ar-H
7 8.06-8.09 2 H doublet Ar-Ha,a’ Jbb ’=9.0
8 11.17 1 H singlet NH(Pyr.) -
Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER Spectrometer
(300 MHz)
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF ETHYL-1-(3-CHLORO-
4 - F L U O R O P H E N Y L ) - 4 - A R Y L - 6 - ( 4 - M E T H O X Y P H E N Y L ) - 3 , 4 -
DIHYDROPYRIMIDIN-2-ONE-5-CARBOXYLATES.
(A) Synthesis of Ethyl-3-(4-methoxyphenyl)-3-oxopropanoate.
See Part-I, Section-II (A).
(B) Synthesis of N-(3-chloro-4-fluorophenyl)urea.
See Part-I, Section-IV (A).
(C) Synthesis of Ethyl-1-(3-chloro-4-fluorophenyl)-4-(3-nitrophenyl)-6-(4-
methoxyphenyl)-3,4-dihydropyrimidin-2-one-5-carboxylate.
A mixture of ethyl-3-(4-methoxyphenyl)-3-oxopropanoate (2.22 gm, 0.01
mol ) ,  N- (3 -ch lo ro -4 - f luo ropheny l )u rea  (1 .88  gm,  0 .01  mol )  and  m-
nitrobenzaldehyde (1.51 gm, 0.01 mol) in 15 ml of ethanol containing few drops of
concentrated hydrochloric acid was refluxed for 24 hrs. The solution was allowed
to stand for 12 hrs. at O
0
C. The resulting solid mass separated was filtered and,
crystallized from dioxane. Yield 45%, m.p.221
0
C, Anal.Calcd. for C26H21CIFN3O6
Calcd: C, 59.38; H, 4.02; N, 7.99%, Found:  C, 59.35; H, 4.01; N, 7.98%.
Similar ly,  other  E thy l -1 - (3 -ch lo ro -4 - f luoropheny l ) -4 -a ry l -6 - (4 -
methoxyphenyl)-3,4-dihydropyrimidin-2-one-5-carboxylates were prepared. The
physical data are recorded in Table No.6
(D) Biological screening of Ethyl-1-(3-chloro-4-fluorophenyl)-4-aryl-6-(4-
methoxyphenyl)-3,4-dihydropyrimidin-2-one-5-carboxylates.
Antimicrobial testing were carried out as described in Part-I Section-I(C).
The zones of inhibition of test solutions are recorded in Graphical Chart No.6
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INTRODUCTION
Thiourea itself was one of the first new drug employed to depress, the clinically
over active thyroid in thyrotoxicosis
1 but some of the cyclic thioureides have been found
better suited. All of these are prone of produce adverse reduction in susceptible patients
and found more potent and less likely to produce side effect and is being used widely.
2
Generally pyrimidine derivatives such as 2-hydroxy pyrimidine, 2-mercapto py-
rimidine and 2-amino pyrimidine are studied. Pyrimidines have been isolated from the
hydrolysis of the nucleic acid.
Pyrimidines are among those molecules that make life possible, have been some
of the building blocks of DNA and RNA. Several analogs of  pyrimidines have been
used as compounds that interfere with the synthesis and functioning of nucleic acids e.g.
fluorouracil, which has been used in cancer treatment. Also there are some thiouracil
derivatives, which produce adverse  reduction in susceptible patients and found more
potent and less likely to produce side effects and is being widely used. There are several
other important groups of pyrimidines with medicinal uses.
Pyrimidine ring carrying various subtituents may be built up from two or three
aliphatic fragments by the principle synthesis or by a variety of other synthesis, which
are complimentary rather than alternative to it. A second type of synthesis is the
isomerisation or break down of another heterocycles such as an hydration of purine but
such roots are frequently used. Pyrimidine is best considered as a resonance hybrid to
which the uncharged equivalent Kekule   structures 1 and 1a and charged  structures 1
and 1a and charged structures 1b and 1g contribute.  The self consistent p (pi) electron
densities required for the ground state of pyrimidine are 0.776, 0.825 and 1.103 for
positions 2, 4 and 5 respectively. Despite considerable localization of p (pi) electrons at
nitrogen atoms of pyrimidines, the ring system is still sufficiently aromatic to possess
substantial stability. This is great advantage in the primary synthesis of pyrimidines.
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 From the theoretical  view point, it is essential to predict the structure, binding
properties, chemical reactivity, etc. of dihydro compounds from the number and
positioning of nitrogen atoms in the ring, as well as from the disposition of double bonds.
Such quantum mechanical calculations also enable an evaluation of the degree of aromatic
character in potential “homoaromatic” and “antiaromatic” isomers. Availability of novel
model compounds for verifying these predictions would open up new horizons in
theoretical heterocyclic chemistry, particularly in clarifying the structures leading to
spontaneous isomerization of a derivative or in verifying its redox properties.
From the biochemical point of view, 1,4-dihydropyrimidine are of intense inter-
est because of presence of this group at the active site of the “hydrogen transferring
coenzyme” NADH (reduced nicotinamide adenine dinucleotide). This nucleotide, a cen-
tral participant in metabolic processes in living organisms, participates in the reduction
of various unsaturated functionalities.
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SYNTHETIC ASPECT :-
(1) Silica Sulfuric acid efficiently catalyzes the three component Biginelli reaction
between an aldehyde, a b-cabonyl compound, and thiourea in ethanol  to
afford the corresponding dihydropyrimidines in high yield.
3
   The catalyst is
reusable and can be applied several times without any decrease in the yield
of the reaction.
(2) Some Biginelli compounds were synthesized by using a photochemistry
method.  The Biginelli three component cyclocondensation reaction in THF
medium using a mixture of b-ketoester or b -diketone, aryl aldehyde and
thiourea under irradiation with a tungstan lamp light to gave DHPM-2-(1H)-
thiones.
4
(3) DHPM was prepared from three component b-diketone, aldehyde and thiourea
coupling in ethanol catalyze by indium(III) tribromide(In Br
3
) .
5,6   This
modified one-pot Biginelli condensation provided not only simple preparation
but also this modified Biginelli reaction was oxygen-bridge.
(4) Subhas D. Bose et al. 
7
 describe a general and practical route for the Biginelli
cyclocondensation reaction using cerium(III) chloride (CeCl
3
) heptahydrate
as the catalyst.  Three different sets of reaction conditions were examined
(I) traditional ethanol reflux (ii) water reflux and (iii) solvent-free conditions.
This is a novel, one-pot combination that not only preserves the simplicity of
Biginelli’s one-pot reaction but also consistently produces excellent yields
CH3 O
EtOOC
+ Ph CHO +
NH2 NH2
S
NH
N
H
Ph
SCH3
EtOOC
Silica H2SO4
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of the DHPM-2(1H)-thiones.
(5) Recently, Indium(III) chloride was emerged as a powerful Lewis catalyst
impar t ing  h igh  reg ion  and chemo se lec t iv i ty  in  var ious  chemica l
transformations. Ranu C.et al.
8
 described a simple synthesis of DHPM-2-
(1H)-thione derivatives, using indium(III) chloride (10 mol %) as a catalyst
from an aldehyde, b-dicarbonbyl compound and thiourea in THF.
(6) A practical and green chemistry approach towards synthesis of DHPM-2-
(1H)-thione without any solvent or catalyst.  This method was developed by
Ranu C. et al.
9  Title compound was prepared from three component b -
diketone, aldehyde and thiourea was heated under stirring at 100-105 0C
afford the corresponding DHPM-2-(1H)-thione in high yield (82%) and purity
(> 95%).
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(7) Recently, Wang L. et al.
10-12
 developed novel one pot Biginelli-type
reaction. Aromatic and aliphatic aldehydes with b-dicarbonbyl compound
and thiourea in presence of catalytic amount of 5 % of Yb(OTf)
3 
at 100
0C for 60-90 minute under solvent free condition proceeded smoothly to
afford the corresponding DHPM thione.
Structural Variation Of Reactoin :-
The original cyclocondensation reaction has been extended widely to include
variation in all three components. If these, the aldehydes component has been varied
to the largest extent and now includes not only many aromatic
13-27
 but also
aliphatic
14,15,22,28-31
 and heterocyclic aldehydes
14,22,29,32-35
can also be used. Particular
interest are reaction where the aldehydes component is derived from a carbohydrate.
In such reaction dihydropyrimidines having a sugar-like moiety at position four (C-
nucleoside analogs)  i.e. (1) or (2) are obtained.
Apart from common alkyl acetoacetates which are employed frequently as
the b-ketoester components, other acetoacetic acid such as benzyl acetoacetate,
28,36
R CHO
NH2 NH2
S
R1 R2
O O
+ +
Yb (OTf)3
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(- ) -methyl  ace toaceta te ,
36
 b -chloroethyl  acetoaceta te ,
37
 2 - furanylmethyl
acetoacetate,
38
 and ethylthio acetoacetate
38
 have been used successfully in the
Biginelli reaction; benzoylacetic acid esters react analogously to form (3). 
28
 Similarly,
ethyl 4-bromo acetoacetate,
34
 and ethyl trifluoromethyl acetoacetate
16
 afford the
corresponding 6-functionalized dihydropyrimidines (4) .
Primary, secondary and tertiary acetoacetamides have been used in place of
ester to produce pyrimidine-5-carboxamides (5). 
17,27,39-42 It should be emphasized
that monosubstituted thioureas from exclusively N-1 substituted dihydropyrimidines
of type (6) .
14,19,28,29,33,38,40,42-46
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N SCH3
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6
In addition to solid-phase adaptions of the traditional three-component
Biginelli condensation, solid-phase variations of the “Atwal modification” of the
Biginelli reaction  have also been reported. Robinett et al.
47
 have disclosed the
synthesis of a 648-member combinatorial library of 1,4-dihydropyrimidines (9) .
3
Towards this end, polymer-bound acetoacetate (7) was subjected to Knoevenagel
condensation with aromatic aldehydes, followed by condensation with isothioureas.
Studies on heterocycles...
136
 The resulting polymer-bound 1,4-dihydropyrimidines (8) were cleaved from the
resin with 50% TFA to produce carboxylic acid (9) .
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One other novel approach to DHPMs has been described by Shutalev et al.
48
is outlined below. This synthesis is based on the condensation of readily available
R-tosyl-substi tuted thioureas (10)  with the (in situ prepared) enolates of
acetoacetates or 1,3-dicarbonyl compounds. The resulting hexahydropyrimidines
(11) need not to be isolated and can be converted directly into DHPMs (12). This
method works particularly well for aliphatic aldehydes and thioureas and produces
high overall yields of the desired target compounds.
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Therapeutic Importants :
Biginelli compound show a diverse range of biological activities. As early as 1930
simple derivatives (13) were patented as agent for the protection of wool against moths.
49
Later, interest focused on the antiviral activity of Biginelli compounds.
50
Pyrimidine-5-carboxamides derivatives of type (14) were reported to possess
anticarcinogencic activity, 
51
 antiinflammaroty, 
27,52
 analgesic 
27
 and blood platelet
aggregation inhibitory activity. 
24
The main interest in Biginelli compounds, however, is due to the strong antihy-
pertensive activity exhibited by certain derivatives. This is not surprising, since these
dihydropyrimidines can be regarded as aza-analogs of dihydropyridines of the nifedipine
type. Dihydropyridines have found widespread use in cardiovascular medicine and have
served as important tools for the study of calcium channel structure and function.
53
Simple modificatios of the aromatic ring are reported to give substances with
only moderate cardiovascular activity, e.g. (13),
25
 (16),
19,54,55
 (17) were shown to be
potent calcium channel blockers,
56-58
 but they do not shown any significant
antihypertensive activity in vivo.
56
 This is also the case for bicyclic dihydropyrimidines
(15).
59,60
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Among the most potent derivatives are Biginelli compounds bearing an
ester group at N-3 (18), thereby closely resembling the nifedipine structure.
61-64
 Al-
though the calcium channel  blocking activity of these compounds, e.g.(19) , is compa-
rable to dihydropyridines, most of them are devoid of antihypertensive activity in vivo.
62
Atwal K. S. et al.
65
 synthesized the 2-[ [ (4-methoxyphenyl)methyl]thio]-
dihydropyrimidine (20) and investigated that pyrimidines are integral parts of such bio-
logically important compounds as antiviral,
66,67 antitumor 68 and cardiovascular agent.
69
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A very recent highlight in this context has been the identification of the structurally
rather simple DHPM monastrol (21) as a novel cell-permeable molecule that blocks
normal bipolar spindle assembly in mammalian cells and therefore causes cell cycle
arrest.
70
 Monastrol specifically inhibits the mitotic kinesin Eg5 motor protein and can be
considered as a new lead for the development of anticancer drugs.
70,71
Out of a library of 16,320 diverse small molecules, Mayer et al.
70  identified
monastrol as a lead compound for the development of new anticancer drugs.  By using
an innovative combination of two phenotype- based screens, one based on a mitosis-
specific posttranslational modification and the other visualizing microtubules and
chromatin, monastrol was recognized as the only cell-permeable compound that is
capable of affecting mitosis in mammalian cells without targeting tubulin.
The design, synthesis and screening of libraries of small organic molecules
possessing privileged structures has become a successful strategy in the drug discovery
process.
72
 The term  privileged structures is generally used to describe those classes
of small organic molecules (<600-700 molecular weight) that have been shown to possess
the ability to bind to a wide range of receptors.
73
  An efficient approach in medicinal
chemistry relies on the identification of this type of scaffolds and their elaboration in a
combinatorial manner with a set of pharmacophoric substituents to generate libraries of
structurally related compounds. The biological screening of these collect ions then
allows the identif ication of drug candidate compounds.
74  The
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 dihydropyrimidine (DHPM) ring represents a heterocyclic structure of remarkable
biological efficiency, as well established through the pharmacological activities exhibited
by various DHPM derivatives that have been identified as potent calcium channel
modulators, orally active antihypertensive agents, antidiabetics and a 1a-adrenoreceptor-
selective antagonists.
75
Incidentally, DHPM derivatives are readily accessible products via the ketoester-
aldehyde-urea (or thiourea) cyclocondensation known as the Biginelli three component
reaction.
76
 Quite recently, the DHPM derivative monastrol (21) was demonstrated to
arrest mitosis in mammalian cells by causing the bipolar mitotic spindle to form a
monoastral microtubule array surrounded by a ring of chromosomes.
70
 This novel action
of monastrol differentiates it from all other known mitotic inhibitors ranging from colchine
to taxol, which instead affect microtubules, the main structural element of the mitotic
spindle. Since its discovery in 1999, several papers have appeared in the literature
reporting on the synthesis,
77,78
 activity,
79-85
  and enantiomeric separation 
77,78,86 of monastrol
and its analogues.
87
 Focusing on factors important for bipolar spindle formation, it has
been demonstrated that monastrol specifically inhibits in vitro  and in vivo the motor
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activity of the mitotic kinesin Eg5, a motor protein required for spindle bipolarity.
70 ,81
The rapid reversibility of monastrol inhibition activity allows for an exact temporal control
over the cell cycle arrest in mitosis, thus confirming this small organic molecule as a new
and powerful research probe of cellular processes.
88
 Furthermore, since compounds
that cause mitotic arrest have shown antitumor activity in humans,
88
 monastrol may serve
as a lead for the development of new anticancer drugs. A recent study established that,
in the case of monastrol, the (S)-enantiomer is more active than both the (R)-enantiomer
and the racemate.
81,82
 Both (S)- and (R)-monastrols abolished basal Eg5ATPase activity,
with the (S)-enantiomer demonstrating a 15-fold higher potency.
82
George C. et al.
89
 prepared dihydropyrimidine (22) was equipotent to
nifedipine and amlodipine in vitro.  In the spontaneously hypertensive rat ,
dihydropyrimidine (22) is both more potent and longer acting than nifedipine and compares
most favorably with the long-acting dihydropyridine derivative amlodipine.
Dihydropyrimidine (22)  has the potential advantage of being a single enantiomer.
Edward J. et al.
90 employ difference infrared spectroscopy to probe structural
changes that occur in the motor protein with monastrol in the presence of either ADP or
ATP.
Sally Ann P. et al.
91
 synthesized 4,6-Bis[(R-carbamoylethyl)thio]-1-
phenylpyrazolo[3,4- d]pyrimidine (23) was identified as a novel adenosine A1receptor
antagonist, antagonizing adenosine-stimulated cyclic adenosine monophosphate
N
N
H
SCH3
COO
CF3
PriOOC N
F22
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generation in guinea pig brain slices.
92,93
Salvatore B. et al.
94 studied the stopped-flow fluorometry indicates that
monastrol inhibits ADP release by forming an Eg5-ADP-monastrol ternary complex.
Monastrol reversibly inhibits the motility of human Eg5. Monastrol has no inhibitory
effect on the following members of the kinesin superfamily: MC5 (Drosophila melanogaster
Ncd), HK379 (H. sapiens conventional kinesin), DKH392 (D. melanogaster conventional
kinesin), BimC1-428 (Aspergillus nidulans BimC), Klp15 (Caenorhabditis elegans C-
terminal motor), or Nkin460GST (Neurospora crassa conventional kinesin).
Atwal K. et al 
62
 synthesized the 3-substituted 1,4-dihydropyrimidine (24)
and show that vasorelaxant activity was critically dependent on the size of the C5 ester
group, isopropyl ester being the best, a variety of substituents (carbamate, acyl, sulfonyl,
alkyl) were tolerated at N3. The dihydropyrimidines (24) are significantly more potent
than corresponding 2-heteroalkyl-l,4-dihydropyrimidines. Dihydropyridine enantiomer
usually show 10-15-fold difference in activity, the enantiomers of dihydropyrimidine (25)
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 show more than a 1000-fold difference in activity. These results strengthen the
requirement of an enamino ester for binding to the dihydropyridine receptor and indicate
a nonspecific role for the N3-substituent.
Atwal K.S.
56
 prepared the 2-heterosubstituted-4-aryl-l,4-dihydro-6-methyl-5
pyrimidinecarboxylic acid esters  which lack the potential C, symmetry of dihydropyridine
calcium channel blockers, were prepared and evaluated for biological activity. Biologi-
cal assays using potassium-depolarized rabbit aorta and radioligand binding techniques
showed that some of these compounds are potent mimics of dihydropyridine calcium
channel blockers. The combination of a branched ester (e.g. isopropyl, sec-butyl) and
an alkylthio group (e.g. SMe) was found to be optimal for biological activity.
Dihydropyrimidines (26) were found to be 30-fold less active. The solid-state structure
of dihydropyrimidine analogue (26) shows that these compounds can adopt a molecular
conformation which is similar to the reported conformation of dihydropyridine calcium
channel blockers.
As a demonstration of this new concept in the Biginelli reaction, the synthesis of
two C4 epimer monastrol analogues bearing the ribofuranosyl moiety at C6 (27),(28),(29)
has been synthesized by Alessandro D. et al.
95
Novel compounds related to 2-(cyclohexylthio)-3,4-dihydro-5-methyl-6-(3-
me thy lbenzy l ) -4 -  oxopyr imid ine (3 0) (  MC 639 )  have  been  syn the s i zed
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N
H
NO2
SCH3
EtOOC
26
Studies on heterocycles...
144
b y  Antonello M. et al.
96 and tested as inhibitors of human immunodeficiency virus type-
1 (HIV-1).
Numerous classes of nonnucleoside reverse transcriptase inhibitors (NNRTIs)
have been discovered by Antonello Mai et al.
97
 with dihydro-alkyloxy-benzyl-
oxopyrimidines (DABOs) being one of them. The lead compound, an isotrimethoprim
derivative (31),(32),(33)   has been synthesized as a possible dihydrofolate reductase
inhibitor, and when tested against HIV-1 because of its structural similarity with HEPT,
98,99
it was a selective, although not very potent, HIV-1 inhibitor.
100
 On the basis of these
findings, various oxopyrimidines have been synthesized and found to be specific HIV-1
inhibitors targeted at the reverse transcriptase.
101-104
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Various 2-thiopyrimidine derivatives have been synthesized by Sondhi  S.M. et
al.
105
 One of the compound, 7,7,8a-trimethyl-hexahydro-thiazolo[3,2-c]pyrimidine-5-
thione (34) showed good anti-inflammatory (37.4% at 100mg/kg p.o.) and analgesic
activity (75% at 100mg/kg p.o.). 7-(1-Mercapto-3,3,4a-trimethyl-4,4a,5,9b-tetrahydro-
3 H - p y r i d o [ 4 , 3 - b ] i n d o l - 7 - y l ) - 3 , 3 , 4 a - t r i m e t h y l - 3 , 4 , 4 a , 5 - t e t r a h y d r o -
benzo[4,5]imidazo[1,2-c]pyrimidine-1-thiol (35)  showed moderate activity against CDK-
1 (IC(50)=5muM). The other compounds showed moderate anti-inflammatory (5-20%),
analgesic (25-75%) and protein kinase (CDK-5, GSK-3) inhibitory activities
(IC(50)>10muM).
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Massey A. et al.
106
 described that 6-thioguanine (S6G) used in treatment of acute
leukaemia. Its cytotoxic effect requires an active DNA mismatch repair (MMR) system.
S6G is incorporated into DNA where a small fraction undergoes in situ conversion to
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S6-thiomethylguanine (S6meG). After replication, S6meG-containing base pairs interact
with MMR. This interaction is ultimately lethal and MMR-defective cells are resistant to
S6G.
Massey A.  et al.
106 report that growing human cells extensively incorporate the
thiopyrimidine nucleoside 4-thiothymidine (S4TdR) into their DNA. The incorporated
thiopyrimidine (S4T) can also undergo facile S-methylation to 4-thiomethylthymine
(S4meT). The rate of methylation of S4TdR in model substrates is similar to that for the
conversion of S6G to S6meG indicating that the DNA of cells grown in S4TdR will
contain significant levels of S4meT.
Twenty 5-alkyl-2-thiopyrimidine nucleosides were newly synthesized by Shigeta
S. et al.
107
 and examined for antiviral activities against herpes simplex virus (HSV),
varicella-zoster virus VZV) and human cytomegalovirus (HCMV). In this study, 2'-deoxy-
5-alkyl-2-thiocytidine (37) analogues had lower 50% effective concentration (EC50)
values against HSV-1, and 2'-deoxy-5-alkyl-2-thiouridine (38) analogues showed lower
EC50 against VZV than their congeners of arabinoside form. Among the
compounds examined, 2'-deoxy-5-ethyl and 5-propyl-2-thiocytidine (39),(40)  were
most potent and selective anti-HSV compounds. Their EC50s were 0.04 and 0.15
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Attia  A. M. et al.
108 synthesized N3-beta-D-glucopyranosyl, galactopyranosyl
and xylopyranosyl 6-methyl-2-methylthiouracil (42) and their 5-bromo derivatives  by
coupling an a -acetobromosugar with the corresponding thiouracil. The new modified
thiouridine analogues were evaluated for their inhibitory activity against Human
Immunodeficiency Virus (HIV) replication in MT-4 cells as well as for their cytotoxicity.
microM, and selectivity indexes were more than 7,215 and 1,849, respectively. On the
other hand, 2'-deoxy-5-propyl-2-thiouridine , 5-bromovinyl-2-thiouracil arabinoside and
5-styryl-2-thiouracil arabinoside (41)  were most potent and selective anti-VZV
compounds. Their EC50s were 3.1, 3.8 and 2.6 pM for CaQu strain of VZV,
respectively, and 2.1 to 3.0 times lower than that of acyclovir. All 2-thiopyrimidine
nucleoside analogues did not show antiviral activities against thymidine kinase (TK)
negative strains of HSV-1 and VZV. Only three 2-thiocytosine arabinoside compounds
showed marginal anti-CMV activities (EC50s were 57-159 pM).
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Twenty 2-thiopyrimidine nucleoside analogues were synthesized by Shigeta S. et
al.
109 and examined for inhibitory activity against herpes simplex virus (HSV) type 1 and
2, varicella-zoster virus (VZV), human cytomegalovirus (HCMV) and thymidine kinase-
deficient HSV (HSV-TK-) replication in vitro .
2-thiouracil (thymine) arabinoside, 2'-deoxy-2-thiouridine (43) and their 5-
halogenated derivatives showed anti-HSV activity in both RPM18226 (human B-
lymphoblastoid cells) and MRC-5 (human embryo lung cells). 2'-Deoxy-5-halogenated-
2-thiocytidines (44) were also inhibitory against HSV, whereas 2-thiocytosine arabinoside
and its derivatives were not inhibitory against HSV replication, except 5-bromo and 5-
iodo congeners.
Substitution of the halogen atom at the 5-position of the pyrimidine rings to an
atom with a higher molecular weight increased anti-HSV and VZV activities, except for
the anti-HSV activity of 2-thiouracil arabinosides. 2'-Deoxy-5-methyl-2-thiouridines (45)
showed the most potent anti-HSV activity,  2'-deoxy-5-chloro- and 2'-deoxy-5-bromo-
2-thiocytidines (46) were potent inhibitors of VZV replication. However, none of the
compounds inhibited HCMV and HSV-TK- replication. 5-Bromo and 5- iodo congenres
were shown to inhibited HCMV and HSV-TK- as well as HSV and VZV
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 replication. The cytotoxicity of the 2-thio-pyrimidine nucleoside analogues was less
than that of the 2-oxy-congeners of the compounds (5-iodo-2'-deoxyuridine, 5-iodo-
2'-deoxycytidine, thymine arabinoside and cytosine arabinoside). The selectivity index
of 2'-deoxy-5-iodo-2-thiouridine was higher than that of 5-iodo-deoxyuridine.The
compound of (45) was not cytotoxic to resting or stimulated human peripheral blood
mononuclear cells at 400 microM.
A series of 5-substituted 2'-deoxy-4'-thiopyrimidine nucleosides was synthesized
by Rahim  S. G. et al.
110 and evaluated as potential antiviral agents. A number of analogues
such as 2'-deoxy-5-propyl-4'-thiouridine, 2'-deoxy-5-isopropyl-4'-thiouridine, 5-
cyclopropyl-2'-deoxy-4'-thiouridine, 2'-deoxy-4'-thio-5-vinyluridine and 5-(2-
chloroethyl)-2'-deoxy-4'-thiouridine (47)  were found to be highly active against herpes
simplex virus type-1 (HSV-1) and varicella zoster virus  in vitro  with no significant
cytotoxicity. The compound with the broadest spectrum of activity was 2'-deoxy-5-
ethyl-4'-thiouridine  which showed significant activity against HSV-1, HSV-2 and VZV.
Massey  A. et al.
111 described the thiopurines, 6-thioguanine(48)  and 6-
mercaptopurine,(49) are antileukemic agents that are incorporated into DNA following
retrieval by the purine salvage pathway.
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Their toxicity requires active DNA mismatch repair (MMR) and thiopurine
resistance is an acknowledged phenotype of MMR-defective cells. In addition to these
direct cytotoxic effects, DNA thiobases have distinctive photochemical properties , the
therapeutic potential of which has not been extensively evaluated.
Novel D- and L-2'-azido-2',3'-dideoxy-4'-thionucleosides were synthesized by
Jeong L.S. et al.
112
 and evaluated for antiviral activity. When the final nucleosides were
tested against HIV-1, HSV-1, HSV-2 and HCMV they were found to be only active
against HCMV without cytotoxicity up to 100 micrograms/ml.
Oxygen-sulfur exchange at the C-4 carbonyl of several modified pyrimidine
nucleosides, including 3'-azido-3'-deoxythymidine (AZT) (50) , is described in an effort
to enhance the lipophilicity and thereby, the delivery to the central nervous system of the
sulfur analogues without compromising the anti-HIV activities of the parental structures.
Compounds  2',3'-didehydro-3'-deoxy-4-thiothymidine (51), 2',3'-didehydro-
2',3'-dideoxyuridine (52) , 2',3'-dideoxy-4-thiouridine (53)  and 3'-deoxy-4-thiothymidine
(54) were evaluated for their effects on HIV-induced cytopathogenicity of MT-2 and
CEM cells by Palomino E. et al.
113  Only (51) and  (54)  were moderately active in
protecting both cell lines against the cytolytic effect of HIV. The inhibitory effects of
analogues (51), (52), (53) and (54) on thymidine phosphorylation by rabbit thymus
thymidine kinase were evaluated. Only (53)  showed moderate affinity (Ki = 54 microM)
for the enzyme.
N
N
H
CH3
O
O
O
OH
N
N
+
N-50
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Yamamoto Y. et al.114  shows that the steric effects of the 2-thiocarbonyl group
and the 2'-hydroxyl group cause the rigidity of the C3'-endo-gg form of 2-
thioribothymidine(s2T) . Such rigidity of s2T probably contributes to the thermostability
of 2-thiopyrimidine polyribonucleotides and extreme thermophile tRNAs.
A new thiopyrimidine derivative has been synthesized by  Bassleer R. et al.
115
 It
can inhibit cell multiplication in Chick embryo fibroblasts, in Mouse Ehrlich ascites tu-
mor cells and in Rat hepatoma cells (line Rueber) cultivated in vitro .
One hundred compounds were evaluatedby Max H. et al.
116 as ligands of Toxo-
plasma gondii  uracil phosphoribosyltransferase (UPRTase, EC 2.4.2.9) by examining
their ability to inhibit this enzyme in vitro . Inhibition was quantified by determining
apparent K
i
 values for those compounds that inhibited T. gondii  UPRTase by greater
than 10% at a concentration of 2 mM. Five compounds (4-thiopyridine, 2-thiopyrimidine,
trithiocyanuric acid (55) , 1-deazauracil and 2,4-dithiouracil (56)) bound to the enzyme
better than two known substrates for T. gondii  UPRTase, 5-fluorouracil and emimycin,
which have antitooplasmal activity. 
117,118
 In addition, several selected compounds were
evaluated as substrates for T. gondii UPRTase, and it was found that 2,4-dithiouracil is
also a substrate for this enzyme.
OH O
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Transfer RNAs isolated by Kwong  L. K. et al.
119
 from Escherichia coli B grown
in the presence of 2-thiouracil are deficient in pseudouridine. Much of this deficiency is
from the T psi C region, which has only about 50% of its normal pseudouridine content.
The other modified nucleoside from this region, ribothymidine, is reduced by only about
10%. Studies showed that 2-thiouracil is incoproated into the RNA of E. coli during
growth in the presence of the analog.
New thiopyrimidine derivatives have been synthesized by Bassleer R. et al.
120
Among them, several inhibit the multiplication of Chick embryo cells cultivated in vitro
they provoke strong nucleolar alterations, prevent the cells from entering into mitosis
and can give rise to cell polyploidisation as to DNA.
Raymond H. et al.
121
 described that mouse kidney thiol transmethylase and S-
adenosylmethionine were incubated with the radioactive antithyroid drugs, 2-thiouracil
(TU), 6-propyl-2-thiouracil (57)  (PTU), methimazole (MMI). 6-Methyl-2-thiouracil (58)
(6-methyl TU) or thiourea. Radioactive metabolites were produced with TU, PTU and
6-methyl TU and, in each case. were identified as the corresponding S-methyl derivatives.
No measurable metabolism of MMI or thiourea was observed.
N
SH
N
SH
N
SH
NH
SN
H
S
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H
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The results obtained demonstrate that S-methylation is a general pathway of
metabolism for thiopyrimidine antithyroid drugs, but not for thiourea or MMI, which
markedly decreases the antiperoxidase activity of the parent compound.
HeLa cells infected with radioactive poliovirus type 2 were disrupted with
ultrasonic treatment, followed by addition of a non-ionic detergent. Two types of virus
particles were found to sediment at 80 to 90% the rate of native virus. The first of these
appeared to be a complex of native virus particles and membrane components, since
treatment with 0-2% SDS released infectious native particles. The second was non-
infectious and its sedimentation rate was not greatly altered by SDS. One hour after
infection this non-infectious particle was the major product of cell-mediated eclipse.
Lonberg-Holm K. et al.
122
 have confirmed that 10 to 30 mg-g/ml S-7, a substituted
thiopyrimidine, blocks infection of cells by poliovirus in a specific manner.
Mazumdar K. et al.
123 analyzed the X-ray fibre diffraction pattern obtained from
synthetic poly-2-thiouridylic acid (poly(s2U)) (59), a 2-thiosubstituted homologue of
polyuridylic acid, reveals that the poly(s2U) homopolymer exists in a structure similar to
that of A -DNA
Further, yeast tRNA
3
Glu contains a 2-thiouridine derivative in the 32 -position
of its anticodon and recognizes GAA but not GAG as the codon for glutamic acid. This
specificity can be explained when considering the preferred S · · · N stacking interactions
which would restrict “wobbling” of the 32 -nucleotide of the anticodon.
Bo Sorbo et al.
124  described that 4-Thiouracil (60) , 4-thiouridine (61) and tRNA
from Escherichia coli were irradiated with X-rays in air-saturated solutions and the
P
O
OH
OH
O
OH
OH
O
N
S
NH
O
59
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 radiolysis of the 4-thiouracil moieties was determined spectrophotometrically. The dose-
effect curves were exponential, giving initial yields of destruction (G value) of 3.22 for
thiouracil, 2.45 for thiouridine and 0.31 for the thiouracil residues in tRNA. The
thiopyrimidine residues were more radiolabile than the corresponding oxygen analogues,
as the G values found for uracil and uridine under the same conditions were 2.28 and
1.83, respectively.
The metabolic fate of three pharmacologically significant thiopyrimidines has been
investigated by Spector E. et al.
125  Incubation of thiamylal (62), 5-allyl-5-(1-
methylbutyl)-2-thiobarbituric acid (63) , with minced rat liver resulted in the formation
of a metabolite which was isolated and identified as secobarbital.
The urine of rats receiving thiouracil, 2-mercapto-4hydroxypyrimidine was
examined by ion exchange and paper chromatography and revealed significant amounts
of uracil. Thiouracil, when incubated with a mince or homogenate of rat liver, was
metabolized at the rate of 280–350 g/g of tissue per 3 hr.
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With an intention of preparing the compounds possessing better therapeutic
activity, we have undertaken the synthesis of dihydropyrimidinthiones which have been
described in following sections
SECTION- I SYNTHESIS AND BIOLOGICAL SCREENING OF 6-
METHYL-N-(4-METHYLPHENYL)-4-ARYL-3,4-DIHYDRO
PYRIMIDIN-2(1H)-THIONE-5-CARBOXAMIDES.
SECTION-I I SYNTHESIS AND BIOLOGICAL SCREENING OF ETHYL-6-
(4-METHOXYPHENYL)-4-ARYL-3,4-DIHYDRO
PYRIMIDIN-2(1H)-THIONE-5- CARBOXYLATES.
SECTION-III SYNTHESIS AND BIOLOGICAL SCREENING OF N-(2,4-DI
CHLOROPHENYL)-6-(4-METHOXYPHENYL)-4-ARYL-3,4-
DIHYDROPYRIMIDIN-2(1H)-THIONE-5-CARBOXAMIDES.
SECTION-I V SYNTHESIS AND BIOLOGICAL SCREENING OF ETHYL-1-
(3-CHLORO-4-FLUOROPHENYL)-4-ARYL-6-METHYL-3,4-
DIHYDROPYRIMIDIN-2-THIONE-5-CARBOXYLATES.
SECTION- V SYNTHESIS AND BIOLOGICAL SCREENING OF 1-(3-
CHLORO-4-FLUORO PHENYL)-4-ARYL-6-METHYL-N-(4-
METHYLPHENYL)-3,4-DIHYDROPYRIMIDIN-2-THIONE-5-
CARBOXAMIDES.
SECTION-VI SYNTHESIS AND BIOLOGICAL SCREENING OF ETHYL-1-(3-
CHLORO-4-FLUOROPHENYL)-4-ARYL-6-(4-METHOXY PHE
NYL)-3,4-DIHYDROPYRIMIDIN-2-THIONE-5-CARBOXYLATES.
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SECTION - I
SYNTHESIS AND BIOLOGICAL SCREENING OF 6-METHYL-N-(4-
METHYLPHENYL)-4-ARYL-3,4-DIHYDROPYRIMIDIN-2(1H)-THIONE-5-
CARBOXAMIDES.
Much interest have been focused around dihydropyrimidinone derivatives
because of their wide variety of pharmacologidal properties and industrial
applications. In view of these findings and achieve to bettr drug potency, we have
synthesized 6-Methyl-N-(4-methylphenyl)-4-aryl-3,4-dihydropyrimidin-2(1H)-
thione-5-carboxamides of Type (I) by the cyclocondensation of N-(4-methylphenyl)-
3-oxobutanamide with thiourea and aryl aldehydes.
The structure elucidation of synthesized compounds has been done on the
basis of elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay
like antibacterial activity towards gram positive and gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40µg/ml.
The biological activities of synthesized compounds were compared with standard
drugs.
Moreover, some selected compounds have been evaluated for their in vitro
biological assay towards a strain of Mycobacterium tuberculosis H37Rv at  a
concentration of 6.25 µg/ml using Rifampin as a standard drug which have been
tested at Tuberculosis Antimicrobial Acquisition Co-ordinating Facility (TAACF),
Alabama, U. S. A.
 Type(I)
 R=Aryl
NH
N
H
R
CH3
O
N
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H
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 Observed
Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode
NMR SPECTRAL STUDIES OF 6-METHYL-N-(4-METHYLPHENYL)-4-
PHENYL-3,4-DIHYDROPYRIMIDIN-2(1H)-THIONE-5-CARBOXAMIDE.
NH
N
H
CH3
O
N
S
CH3
H
Alkane C-H str. (asym.) 2916 2975-2950 126
-CH3 C-H str. (sym.) 2866 2880-2860  , ,
C-H i.p.def. (asym.) 1438 1470-1435  , ,
C-H o.o.p. def. (sym.) 1326 1390-1370  , ,
Aromatic C-H  str. 3010 3090-3030 127
C=C str. 1487 1540-1480  , ,
1402 1520-1480  ,,
C-H i.p. (def.) 1078 1125-1090  , ,
C-H o.o.p. (def) 810 835-810  , ,
Pyrimidine C=C str. 1589 1580-1520  , ,
   moity C-H str. 3060 3080-3030  , ,
C-H i.p. def. 1103 1125-1090  , ,
Amine -NH str. 3431 3410-3380 126
-NH def. 1629 1635-1595  , ,
Amide - C=O str 1678 1690-1660          , ,
0.0
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cm
 412.7
 441.7
 507.2
 543.9
 605.6
 646.1
 698.2
 756.0
 810.0
 889.1
 927.7
1022.2
1078.1
1103.2
1184.2
1205.4
1236.3
1305.7
1326.9
1346.2
1402.2
1438.8
1487.0
1517.91589.2
1629.7
1678.0
1897.8
2866.0
2916.2
3010.7
3060.8
3186.2
3284.53431.1
Instrument : SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 4000-400 cm-1
(KBr disc.)
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NH
N
H
CH3
O
N
S
CH3
Ha
b
a'
b'
c
NMR SPECTRAL STUDIES OF 6-METHYL-N-(4-METHYLPHENYL)-4-
PHENYL-3,4-DIHYDROPYRIMIDIN-2(1H)-THIONE-5-CARBOXAMIDE.
1 2.15 3 H singlet -CH3(Pyr.) -
2 2.26 3 H singlet Ar-CH3 -
3 5.50 1 H singlet Ar-Hc -
4 7.01-7.04 2 H doublet Ar-Ha,a’ Jaa ’=9.0
5 7.31 5 H multiplate Ar-H -
6 7.37-7.40 2 H doublet Ar-Hb,b’ Jbb ’=9.0
7 9.06 1 H singlet -NH(Amide) -
8 9.18 1 H singlet -NH(Pyr.) -
9 9.60 1 H singlet -NH(Pyr.) -
Signal
  No.
Signal Position
    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER Spectrometer
(300 MHz)
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF 6-METHYL-N-(4-
METHYLPHENYL)-4-ARYL-3,4-DIHYDROPYRIMIDIN-2(1H)-THIONE-5-
CARBOXAMIDES.
(A) Synthesis of N-(4-methylphenyl)-3-oxobutanamide.
           See Part-I, Section-I (A).
(B) Synthes i s  o f  6-Methyl-N-(4-methylphenyl)-4-phenyl-3,4-dihydro
pyrimidin-2(1H)-thione-5-carboxamide.
A mixture of thiourea (0.76 gm, 0.01 mol), benzaldehyde (1.06 gm, 0.01
mol) and  N-(4-methylphenyl)-3-oxobutanmide (1.91 gm, 0.01 mol) in 15 ml of
ethanol containing few drops of concentrated hydrochloric acid was refluxed for 24
hrs. The solution was allowed to stand for 12 hrs. at O
0
C. The resulting solid mass
separated was filtered and crystallized from dioxane. Yield 41%, m. p. 242
0
C,
Anal.Calcd. for C19H19N3OS Calcd: C, 67.63; H, 5.68; N, 12.45%, Found:  C,
67.61; H, 5.67; N, 12.44%.
Similarly, other 6-Methyl-N-(4-methylphenyl)-4-aryl-3,4-dihydropyrimidin-
2(1H)-thione-5-carboxamides  were prepared. The physical data are recorded in
Table No. 7
(C) Biological screening of  6-Methyl-N-(4-methylphenyl)-4-aryl-3,4-
dihydropyrimidin-2(1H)-thione-5-carboxamides.
Antimicrobial testing were carried out as described in Part-I Section-I(C).
The zones of inhibition of test solutions are recorded in Graphical Chart No.7
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7a 179650 ZP-14 C6H5 - Alamar H37R v >6.25 00
7b 179651 ZP-15 2-Cl-C6H4 - Alamar H37R v >6.25 25
7c 179652 ZP-16 3-Cl-C6H4 - Alamar H37R v >6.25 09
7d 179653 ZP-17 4-F-C6H4 - Alamar H37R v >6.25 19
7e 179654 ZP-18 2-NO2-C6H4 - Alamar H37R v >6.25 33
7f 179655 ZP-19 3-NO2-C6H4 - Alamar H37R v >6.25 00
7g 179656 ZP-20 C10H7 - Alamar H37R v >6.25 61
7h 179657 ZP-21 3-OCH3-C6H4 - Alamar H37R v >6.25 00
7i 179658 ZP-22 4-OCH3-C6H4 - Alamar H37R v >6.25 07
7j 179659 ZP-23 2,5-(OCH3)2-C6H3 - Alamar H37R v >6.25 00
7k 179660 ZP-24 2-OH-C6H4 - Alamar H37R v >6.25 30
7l 179661 ZP-25 3-C6H5 O-C6H4 - Alamar H37R v >6.25 27
  Sr.
  No.
Sample
   ID
 Corp
   ID
R Assay    Mtb
Strain
     %
Inhibi.
   MIC
 mg/ml
  TABLE  NO-7
TAACF, Southern Research Insitute
Primary Assay Summary Report
NAID/Southern Research Insitute/GWL Hansen’s Disease Centre/Colorado State
University proprietary Information
NH
N
H
CH3
O
N
S
CH3
R
H
ANTITUBERCULAR ACTIVITY O F 6-METHYL-N-(4-METHYLPHENYL)-
4-ARYL-3,4-DIHYDROPYRIMIDIN-2(1H)-THIONE-5-CARBOXAMIDES.
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SECTION - II
SYNTHSIS AND BIOLOGICAL SCREENING OF ETHYL-6-(4-METHOXY
P H E N Y L ) - 4 - A RY L - 3 , 4 - D I H Y D R O P Y R I M I D I N - 2 ( 1 H ) - T H I O N E - 5 -
CARBOXYLATES.
Compounds containing pyrimidine ring are widely distributed in nature. Many
of these derivatives are reported to possess different biological activities. In view
of these report, we have synthesized Ethyl-6-(4-methoxyphenyl)-4-aryl-3,4-
dihydropyrimidin-2(1H)-thione-5-carboxylates of Type (II) by the condensation of
ethyl-3-(4-methoxyphenyl)-3-oxopropanoate, thiourea and aryl aldehydes.
The structure elucidation of synthesized compounds has been done on the
basis of elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay
like antibacterial activity towards gram positive and gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40µg/ml.
The biological activities of synthesized compounds were compared with standard
drugs.
Type(II)
R=Aryl
NH
N
H
R
S
O
CH3
O
OCH3
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 Observed
Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode
IR SPECTRAL STUDIES OF ETHYL-6-(4-METHOXYPHENYL)-4-( 3 -
N I T R O P H E N Y L ) - 3 , 4 - D I H Y D R O P Y R I M I D I N - 2 ( 1 H ) - T H I O N E - 5 -
CARBOXYLATE.
NH
N
H
S
O
CH3
O
OCH3
NO2
  Alkane C-H str. (asym.) 2935 2975-2950 126
  -CH3 C-H str. (sym.) 2844 2880-2860  , ,
C-H i.p.def. (asym.) 1423 1470-1435  , ,
C-H o.o.p. def. (sym.) 1355 1390-1370  , ,
  Aromatic C-H  str. 3190 3090-3030 127
C=C str. 1510 1540-1480  , ,
1461 1520-1480  ,,
C-H i.p. (def.) 1095 1125-1090  , ,
C-H o.o.p. (def) 808 835-810  , ,
  Pyrimidine C=C str. 1596 1580-1520  , ,
     moity C-H str. 3068 3080-3030  , ,
C-H i.p. def. 1066 1125-1090  , ,
  Amine -NH str. 3406 3410-3380 126
-NH def. 1649 1635-1595  , ,
  Ester - C=O str 1718 1690-1660          , ,
0.0
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cm
 478.3
 515.0
 553.5
 582.5
 621.0
 657.7
 682.8
 704.0
 740.6
 808.1
 846.7
 889.1
 929.6
1018.3
1066.6
1095.5
1168.8
1199.6
1261.4
1315.4
1355.9
1423.4
1461.9
1510.2
1533.3
1560.3
1596.9
1649.0
1718.5
2844.8
2935.5
3068.5
3190.0
3406.1
Instrument : SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 4000-400 cm-1
(KBr disc.)
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NMR SPECTRAL STUDIES OF ETHYL-6-(4-METHOXYPHENYL)-4-( 3 -
N I T R O P H E N Y L ) - 3 , 4 - D I H Y D R O P Y R I M I D I N - 2 ( 1 H ) - T H I O N E - 5 -
CARBOXYLATE.
Signal
  No.
Signal Position
    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
1 0.91 3 H triplet -CH3 -
2 3.61 3 H singlet Ar-OCH3 -
3 3.91 2 H quatret -CH2 -
4 5.46 1 H singlet Ar-Hc -
5 6.84-6.87 2 H doublet Ar-Hb,b’ Jaa ’=9.0
6 7.50-7.71 5 H multiplet Ar-H
7 8.71-8.74 2 H doublet Ar-Ha,a’ Jbb ’=9.0
8 8.96 1 H singlet NH(Pyr.) -
9 9.72 1 H singlet NH(Pyr.) -
Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER Spectrometer
(300 MHz)
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF ETHYL-6-(4-METHOXY
P H E N Y L ) - 4 - A RY L - 3 , 4 - D I H Y D R O P Y R I M I D I N - 2 ( 1 H ) - T H I O N E - 5 -
CARBOXYLATES.
(A) Synthesis of Ethyl-3-(4-methoxyphenyl)-3-oxopropanoate.
See Part-I, Section-II (A).
(B) Synthesis of Ethyl-6-(4-methoxyphenyl)-4-(3-nitrophenyl)-3,4-dihydro
pyrimidin-2(1H)-thione-carboxylate.
A mixture of thiourea (0.76 gm, 0.01 mol), m-nitrobenzaldehyde (1.51 gm,
0.01 mol) and ethyl-3-(4-methoxyphenyl)-3-oxopropanoate (2.22 gm, 0.01 mol) in
15 ml of ethanol containing few drops of concentrated hydrochloric acid was refluxed
for 24 hrs. The solution was allowed to stand for 12 hrs. at O
0
C. The resulting solid
mass separated was filtered and, crystallized from dioxane.Yield 47%, m.p.247
0
C,
Anal.Calcd. for C20H19N3O5S Calcd: C,58.10; H, 4.63; N, 10.16%, Found:  C,
58.9; H, 4.62; N, 10.14%.
Similarly, other Ethyl-6-(4-methoxyphenyl)-4-aryl-3,4-dihydropyrimidin-
2(1H)-thione-5-carboxylates  were prepared. The physical data are recorded in Table
No. 8
(C) Biological screening Ethyl-6-(4-methoxyphenyl)-4-aryl-3,4-dihydro-
pyrimidin-2(1H)-thione-5-carboxylates.
Antimicrobial testing were carried out as described in Part-I Section-I(C).
The zones of inhibition of test solutions are recorded in Graphical Chart No.8
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SECTION - III
SYNTHESIS AND BIOLOGICAL SCREENING OF N-(2,4-
D I C H L O R O P H E N Y L ) - 6 - ( 4 - M E T H O X Y P H E N Y L ) - 4 - A RY L - 3 , 4 -
DIHYDROPYRIMIDIN-2(1H)-THIONE-5-CARBOXAMIDES.
Dihydropyrimidinthione derivatives have been found to be associated with
various pharmacological activities. Looking to the interesting therapeutic activity,
i t  was  cons ide red  wor thwhi l e  t o  syn thes i zed  compounds  bea r ing
dihydropyrimidinthione moiety. Dihydropyrimidinthione derivative of type (III) have
been synthes ised by the  condensat ion of   N-(2 ,4-d ich lorophenyl ) -3- (4-
methoxyphenyl)-3-oxopropanamide with thiourea and aryl aldehydes.
The structure elucidation of synthesized compounds has been done on the
basis of elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay
like antibacterial activity towards gram positive and gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40µg/ml.
The biological activities of synthesized compounds were compared with standard
drugs.
Moreover, some selected compounds have been evaluated for their in vitro
biological assay towards a strain of Mycobacterium tuberculosis H37Rv at  a
concentration of 6.25 µg/ml using Rifampin as a standard drug which have been
tested at Tuberculosis Antimicrobial Acquisition Co-ordinating Facility (TAACF),
Alabama, U. S. A.
Type(III)
R=Aryl
NH
N
H
R
O
CH3
O
N
ClCl
S
H
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 Observed
Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode
0.0
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cm
 426.2
 453.2
 489.9
 513.0
 543.9
 609.5
 698.2
 765.7
 819.7
 893.0
 939.3
 999.1
1029.9
1068.5
1139.9
1182.3
1251.7
1315.4
1340.4
1369.4
1406.01452.3
1512.1
1542.9
1602.7
1647.1
1683.7
2802.4
2854.5
2923.9
2949.0
3028.0
3064.7
3124.5
3190.0
3246.034 3.1
IR SPECTRAL STUDIES OF N-(2,4-DICHLOROPHENYL)-6-(4-METH
OXYPHENYL)-4-PHENYL-3,4-DIHYDROPYRIMIDIN-2(1H)- T H I O N E - 5 -
CARBOXAMIDE.
NH
N
H
O
CH3
O
N
ClCl
S
H
  Alkane C-H str. (asym.) 2923 2975-2950 126
   -CH3 C-H str. (sym.) 2854 2880-2860   , ,
C-H i.p.def. (asym.) 1452 1470-1435   , ,
C-H o.o.p. def. (sym.) 1369 1390-1370   , ,
  Aromatic C-H  str. 3064 3090-3030 127
C=C str. 1406 1540-1480   , ,
C-H i.p. (def.) 1068 1125-1090   , ,
C-H o.o.p. (def) 819 835-810   , ,
  Pyrimidine C=C str. 1542           1580-1520   , ,
    moity C-H str. 3028 3080-3030   , ,
C-H i.p. def. 1139 1125-1090   , ,
  Amine -NH str. 3432 3410-3380 126
-NH def. 1602 1635-1595   , ,
  Amide - C=O str 1683 1690-1660         , ,
  Halide -C-CI str. 765 700-750   , ,
Instrument : SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 4000-400 cm-1
(KBr disc.)
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NH
N
H
O
CH3
O
N
ClCl
S
H
a'
b'
c
a
b
NMR SPECTRAL STUDIES OF N-(2,4-DICHLOROPHENYL)- 6 - ( 4 - M E T H
OXYPHENYL)-4-PHENYL-3,4-DIHYDROPYRIMIDIN-2(1H)- T H I O N E - 5 -
CARBOXAMIDE.
Signal
  No.
Signal Position
    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
1 3.91 3 H singlet Ar-OCH3 -
2 5.56 1 H singlet Ar-Hc -
3 6.97-7.00 2 H doublet Ar-Hb,b’ Jaa ’=9.0
4 7.25-7.37 8 H multiplet Ar-H -
5 7.56-7.59 2 H doublet Ar-Ha,a’ Jbb ’=9.0
6 8.87 1 H singlet -NH(Amide) -
Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER Spectrometer
(300 MHz)
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF N - ( 2 , 4 -
D I C H L O R O P H E N Y L ) - 6 - ( 4 - M E T H O X Y P H E N Y L ) - 4 - A RY L - 3 , 4 -
DIHYDROPYRIMIDIN-2(1H)-THIONE-5-CARBOXAMIDES.
(A) Synthesis of Synthesis of Ethyl-3-(4-methoxyphenyl)-3-oxopropanoate.
See Part-I, Section-II (A).
(B) Synthesis of N-(2,4-dichlorophenyl)-3-(4-methoxyphenyl)-3-oxopropa-
namide.
See Part-I, Section-III (B).
(C) Synthesis of N-(2,4-Dichlorophenyl)-6-(4-methoxyphenyl)-4-phenyl-3,4-
dihydropyrimidin-2(1H)-thione-5-carboxamide.
A mix tu re  o f  N- (2 ,4 -d ich lo ropheny l ) -3 - (4 -me thoxypheny l ) -3 -
oxopropanamide (3.38 gm, 0.01 mol), thiourea (0.76 gm, 0.01 mol) and benzaldehyde
(1.06 gm, 0.01 mol) in 15 ml of ethanol containing few drops of concentrated
hydrochloric acid was refluxed for 24 hrs. The solution was allowed to stand for 12
hrs. at O
0
C. The resulting solid mass separated was filtered and, crystallized from
dioxane. Yield 36%, m.p.258
0
C, Anal.Calcd. for C24H19Cl2N3O2S Calcd: C, 59.51;
H, 3.95; N, 8.67%, Found:  C, 59.49; H, 3.93; N, 8.66%
Similarly, other N-(2,4-Dichlorophenyl)-6-(4-methoxyphenyl)-4-aryl-3,4-
dihydropyrimidin-2(1H)-thione-5-carboxamides were prepared. The physical data
are recorded in Table No.9
(C) Biological screening of N-(2,4-Dichlorophenyl)-6-(4-methoxyphenyl)-4-
aryl-3,4-dihydropyrimidin-2(1H)-thione-5-carboxamides.
Antimicrobial testing were carried out as described in Part-I Section-I(C).
The zones of inhibition of test solutions are recorded in Graphical Chart No.9
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9a 179676 ZP-40 C6H5 - Alamar H37R v >6.25 40
9b 179677 ZP-41 2-Cl-C6H4 - Alamar H37R v >6.25 00
9c 179678 ZP-42 3-Cl-C6H4 - Alamar H37R v >6.25 00
9d 179679 ZP-43 2-OH-4-OCH3-C6H3 Alamar H37R v >6.25 52
9e 179680 ZP-44 2-NO2-C6H4 - Alamar H37R v >6.25 00
9f 179681 ZP-45 3-NO2-C6H4 - Alamar H37R v >6.25 18
9g 179682 ZP-46 C10H7 - Alamar H37R v >6.25 24
9h 179683 ZP-47 3-OCH3-C6H4 - Alamar H37R v >6.25 33
9i 179684 ZP-48 4-OCH3-C6H4 - Alamar H37R v >6.25 41
9j 179685 ZP-49 4-Cl-C6H4 - Alamar H37R v >6.25 00
9k 179686 ZP-50 2-OH-C6H4 - Alamar H37R v >6.25 00
9l 179687 ZP-51 4-N(CH3 )2-C6H4 - Alamar H37R v >6.25 34
  Sr.
  No.
Sample
   ID
 Corp
   ID
R Assay    Mtb
Strain
     %
Inhibi.
   MIC
 mg/ml
  TABLE  NO-9
TAACF, Southern Research Insitute
Primary Assay Summary Report
NAID/Southern Research Insitute/GWL Hansen’s Disease Centre/Colorado State
University proprietary Information
NH
N
H
O
N
S
Cl
R
H
Cl
O
CH3
ANTITUBERCULAR ACTIVITY OF N-(2,4-DICHLOROPHENYL)-6-(4-
METHOXYPHENYL)-4-ARYL-3,4-DIHYDROPYRIMIDIN-2(1H)-THIONE-
5-CARBOXAMIDES.
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SECTION - IV
SYNTHESIS AND BIOLOGICAL SCREENING OF ETHYL-1-(3-CHLORO-
4-FLUOROPHENYL)-4-ARYL-6-METHYL-3,4-DIHYDROPYRIMIDIN-2-
THIONE-5-CARBOXYLATES.
 Dihydropyrimidinthione derivatives constitute an interesting class of
comopounds because of thier varied medicinal applications. In order to explor the
activities associated with the nucleus, the synthesis of dihydropyrimidinthione
der ivat ives  of  type  ( IV)  has  been under taken by the  cyclocondensat ion
ethylacetoacetate,N-(3-chloro-4-fluorophenyl)thiourea  and aryl aldehydes.
The structure elucidation of synthesized compounds has been done
on the basis of elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay
like antibacterial activity towards gram positive and gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40µg/ml.
The biological activities of synthesized compounds were compared with standard drugs.
Moreover, some selected compounds have been evaluated for their in vitro
biological assay towards a strain of Mycobacterium tuberculosis H37Rv at  a
concentration of 6.25 µg/ml using Rifampin as a standard drug which have been
tested at Tuberculosis Antimicrobial Acquisition Co-ordinating Facility (TAACF),
Alabama, U. S. A.
Type(IV)
R=Aryl
NH
N
R
CH3 S
F
Cl
O
OCH3
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 Observed
Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode
IR SPECTRAL STUDIES OF  ETHYL-1-(3-CHLORO-4-FLUORO
PHENYL)-4-(3-NITROPHENYL)-6-METHYL-3,4-DIHYDROPYRIMIDIN-2-
THIONE-5- CARBOXYLATE.
NH
NCH3 S
F
Cl
O
OCH3
NO2
  Alkane C-H str. (asym.) 2931 2975-2950 126
  -CH3 C-H str. (sym.) 2839 2880-2860  , ,
C-H i.p.def. (asym.) 1460 1470-1435  , ,
C-H o.o.p. def. (sym.) 1342 1390-1370  , ,
  Aromatic C-H  str. 3006 3090-3030 127
C=C str. 1423 1540-1480  , ,
C-H i.p. (def.) 1060 1125-1090  , ,
C-H o.o.p. (def) 829 835-810  , ,
  Pyrimidine C=C str. 1546 1580-1520  , ,
     moity C-H str. 3031 3080-3030  , ,
C-H i.p. def. 1083 1125-1090  , ,
  Amine -NH str. 3394 3410-3380 126
-NH def. 1618 1635-1595  , ,
  Ester - C=O str. 1705 1690-1660          , ,
  Halide -C-CI str. 750 700-750  , ,
0.0
20.0
40.0
60.0
80.0
100.0
120.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cm
 445.5
 532.3
 609.5
 638.4
 696.3
 719.4
 750.3
 829.3
 964.3
1002.9
1028.0
1060.8
1083.9113 .2
1159.1
1234.4
1261.4
1303.8
1342.4
1380.9
1423.4
1460.0
1514.0
1546.8
1593.11618.21705.0
2341.4
2839.0
2931.6
3006.831.9
3394.5
Instrument : SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 4000-400 cm-1
(KBr disc.)
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NH
NCH3 S
F
Cl
O
OCH3
NO2
c
NMR SPECTRAL STUDIES OF  ETHYL-1-(3-CHLORO-4-FLUORO
PHENYL)-4-(3-NITROPHENYL)-6-METHYL-3,4-DIHYDROPYRIMIDIN-2-
THIONE-5- CARBOXYLATE.
Signal
  No.
Signal Position
    (dppm)
 Relative No.
  of protons
Multiplicity Inference
   J Value
    In Hz
1 1.22 3 H triplet -CH3     -
2 2.20 3 H singlet Ar-CH3     -
3 4.76 2 H quatret -CH2     -
4 5.56 1 H singlet Ar-Hc     -
5 7.21-8.33 7 H multiplet Ar-H     -
6 10.04 1 H singlet NH(Pyr.)     -
Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER Spectrometer
(300 MHz)
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF ETHYL-1-(3-CHLORO-
4-FLUOROPHENYL)-4-ARYL-6-METHYL-3,4-DIHYDROPYRIMIDIN-2-
THIONE-5-CARBOXYLATES.
(A) Synthesis of N-(3-chloro-4-fluorophenyl)thiourea.
           A mixture of 3-chloro-4-fluoroaniline (1.45 gm 0.01 mol), concentrated HCI
30% (10 ml) and ammonium thiocyanate (1.52 gm 0.02 mol) in water as solvent
was refluxed for 10-12 hrs. The resulting mixture was poured into ice water. Excess
of hydrochloric acid and ammonium thiocyanate were removed with hot water and
crude product was isolated and crystallised in methanol. Yield 89%, m.p.236
0
C,
Anal.Calcd. for C7H6CIFN2S Calcd: C, 41.04; H, 2.96; N, 13.69%, Found:  C,
41.03; H, 2.95; N, 13.65%.
(B) Synthesis of Ethyl-1-(3-chloro-4-fluorophenyl)-4-(3-nitrophenyl)-6-
methyl-3,4-dihydropyrimidin-2-thione-5-carboxylate.
A mixture of ethyl acetoacetate (1.30 gm, 0.01 mol), N-(3-chloro-4-
fluorophenyl)thiourea (2.04 gm, 0.01 mol) and m-nitrobenzaldehyde (1.51 gm, 0.01
mol) in 15 ml of ethanol containing few drops of concentrated hydrochloric acid
was refluxed for 24 hrs. The solution was allowed to stand for 12 hrs. at O
0
C. The
resulting solid mass separated was filtered and crystallized from dioxane. Yield 32%,
m.p.269
0
C, Anal.Calcd. for C20H17CIFN3O4S Calcd: C, 55.39; H, 3.81; N, 9.34%,
Found:  C, 55.37; H, 3.80; N, 9.33%.
Similarly, other Ethyl-1-(3-chloro-4-fluorophenyl)-4-aryl-6-methyl-3,4-
dihydropyrimidin-2-thione-5-carboxylates were prepared. The physical data are
recorded in Table No.10
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(C) Biological screening of  Ethyl-1-(3-chloro-4-fluorophenyl)-4-aryl-6-
methyl-3,4-dihydropyrimidin-2-thione-5-carboxylates.
Antimicrobial testing were carried out as described in Part-I Section-I(C).
The zones of inhibition of test solutions are recorded in Graphical Chart No.10
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10a 182341 ZP-53 C6H5 - Alamar H37R v >6.25 45
10b 182342 ZP-54 2-Cl-C6H4 - Alamar H37R v >6.25 32
10c 182343 ZP-55 3-Cl-C6H4 - Alamar H37R v >6.25 00
10d 182344 ZP-56 3-Br-C6H4 - Alamar H37R v >6.25 24
10e 182345 ZP-57 4-F-C6H4 - Alamar H37R v >6.25 06
10f 182346 ZP-58 4-OCH3-C6H4 - Alamar H37R v >6.25 48
10g 182347 ZP-59 4-OH-C6H4 - Alamar H37R v >6.25 00
10h 182348 ZP-60 2-OH-C6H4 - Alamar H37R v >6.25 00
10i 182349 ZP-61 2-NO2-C6H4 - Alamar H37R v >6.25 51
10j 182350 ZP-62 3-NO2-C6H4 - Alamar H37R v >6.25 37
10k 182351 ZP-63 4-N(CH3 )2-C6H4 - Alamar H37R v >6.25 00
10l 182352 ZP-64 2-OH-4-OCH3-C6H3 Alamar H37R v >6.25 00
  Sr.
  No.
Sample
   ID
 Corp
   ID
R Assay    Mtb
Strain
     %
Inhibi.
   MIC
 mg/ml
  TABLE  NO-10
TAACF, Southern Research Insitute
Primary Assay Summary Report
NAID/Southern Research Insitute/GWL Hansen’s Disease Centre/Colorado State
University proprietary Information
N
H
N
O
EtO
S
R
CH3
Cl
F
ANTITUBERCULAR ACTIVITY  OF ETHYL-1-(3-CHLORO-4-
FLUOROPHENYL)-4-ARYL-6-METHYL-3,4-DIHYDROPYRIMIDIN-2-
THIONE-5-CARBOXYLATES.
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SECTION - V
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-(3-CHLORO-4-
FLUOROPHENYL)-4-ARYL-6-METHYL-N-(4-METHYLPHENYL)-3,4-
DIHYDROPYRIMIDIN-2-THIONE-5-CARBOXAMIDES.
Looking to the intresting pharmacological and agriculture activity of
pyrimidine ring system, it was considered worthwhile to synthesized some new
dihydropyrimidinthione derivatives of type (VIII) to study their biological activities.
Dihydropyrimidinthione derivatives of type (VIII) have been prepared by the reaction
of the  N-(4-methylphenyl)-3-oxobutanamide,N-(3-chloro-4-fluorophenyl)thiourea
and aryl aldehydes
The structure elucidation of synthesized compounds has been done on the
basis of elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay
like antibacterial activity towards gram positive and gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40µg/ml.
The biological activities of synthesized compounds were compared with standard
drugs.
Type(V)
R=Aryl
NH
N
R
CH3
O
N
S
CH3
F
Cl
H
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CH3
O
N
CH3
O
H
O H
NO2
NH2
NH S
Cl
F
+
EthanolH
+
NH
NCH3
O
N
S
CH3
H
Cl
F
NO2
Reaction Scheme
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 Observed
Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode
IR SPECTRAL STUDIES OF 1-(3-CHLORO-4-FLUORPHENYL)-4-(3-
NITROPHENYL)-6-METHYL-N-(4-METHYLPHENYL)-3,4-DIHYDRO
PYRIMIDIN-2-THIONE-5-CARBOXAMIDE.
Alkane C-H str. (asym.) 2979 2975-2950 126
-CH3 C-H str. (sym.) 2854 2880-2860  , ,
C-H i.p.def. (asym.) 1425 1470-1435  , ,
C-H o.o.p. def. (sym.) 1328 1390-1370  , ,
Aromatic C-H  str. 3105 3090-3030 127
C=C str. 1465 1540-1480  , ,
C-H i.p. (def.) 1118 1125-1090  , ,
C-H o.o.p. (def) 821 835-810  , ,
Pyrimidine C=C str. 1542 1580-1520  , ,
   moity C-H str. 3026 3080-3030  , ,
C-H i.p. def. 1139 1125-1090  , ,
Amine -NH str. 3408 3410-3380 126
-NH def. 1573 1635-1595  , ,
Amide - C=O str. 1670 1690-1660        , ,
Halide -C-CI str. 761 700-750  , ,
N
H
N
CH3
O
NH
S
F
Cl
CH3
NO2
0.0
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cm
 424.3
 472.5
 503.4
 543.9
 569.0
 596.0
 651.9
 692.4
 723.3
 761.8
 821.6
 869.8
 916.1
1001.0
1028.0
1118.6
1176.51195.8
1263.3
1282.6
1328.9
1371.3
1425.3
1465.8
1573.8
1670.2
2216.1
2854.5
2979.8
3026.1
3105.2
3174.6
3327.0
3408.0
Instrument : SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 4000-400 cm-1
(KBr disc.)
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NMR SPECTRAL STUDIES OF 1-(3-CHLORO-4-FLUORPHENYL)-4-(3-
NITROPHENYL)-6-METHYL-N-(4-METHYLPHENYL)-3,4-DIHYDRO
PYRIMIDIN-2-THIONE-5-CARBOXAMIDE.
Signal
  No.
Signal Position
    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
1 2.17 3 H singlet -CH3(Pyr.) -
2 2.31 3 H singlet Ar-CH3 -
3 5.51 1 H singlet Ar-Hc -
4 7.19-7.22 2 H doublet Ar-Ha,a’ Jaa ’=9.0
5 7.29-7.49 7H          multiplate Ar-H -
6 7.68-7.71 2 H doublet Ar-Hb,b’ Jbb ’=9.0
7 10.06 1 H singlet -NH(Amide) -
8 10.17 1 H singlet -NH(Pyr.) -
NH
NCH3
O
N
S
CH3
F
Cl
H
NO2
a
b
a'
b'
c
Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER Spectrometer
(300 MHz)
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-(3-CHLORO-4-
FLUOROPHENYL)-4-ARYL-6-METHYL-N-(4-METHYLPHENYL)-3,4-
DIHYDROPYRIMIDIN-2-THIONE-5-CARBOXAMIDES.
(A) Synthesis of N-(4-methylphenyl)-3-oxobutanamide.
See Part-I, Section-I (A).
(B) Synthesis of N-(3-chloro-4-fluorophenyl)thiourea.
See Part-I, Section-IV (A).
(C) Synthesis of 1-(3-Chloro-4-fluorophenyl)-4-(3-nitrophenyl)-6-methyl-N-
(4-methylphenyl)-3,4-dihydropyrimidin-2-thione-5-carboxamide.
A mixture of N-(4-methyl phenyl)-3-oxobutanmide (1.91 gm, 0.01 mol), N-
(3-chloro-4-fluorophenyl)thiourea (2.04 gm, 0.01 mol) and m-nitrobenzaldehyde
(1.51 gm, 0.01 mol) in 15 ml of ethanol containing few drops of concentrated
hydrochloric acid was refluxed for 24 hrs. The solution was allowed to stand for 12
hrs. at O
0
C. The resulting solid mass separated was filtered and crystallized from
dioxane. Yield 48%, m.p.214
0
C, Anal.Calcd. for C25H20CIFN4O3S Calcd: C, 58.76;
H, 3.95; N, 10.96%, Found:  C, 58.75; H, 3.93; N, 10.94%.
Similarly, other 1-(3-Chloro-4-f luorophenyl)-4-aryl-6-methyl-N-(4-
methylphenyl)-3,4-dihydropyrimidin-2-thione-5-carboxamides were prepared. The
physical data are recorded in Table No.11
(D) Biological screening of 1-(3-Chloro-4-fluorophenyl)-4-aryl-6-methyl-N-
(4-methylphenyl)-3,4-dihydropyrimidin-2-thione-5-carboxamides.
Antimicrobial testing were carried out as described in Part-I Section-I(C).
The zones of inhibition of test solutions are recorded in Graphical Chart No.11
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SECTION - VI
SYNTHESIS AND BIOLOGICAL SCREENING OF ETHYL-1-(3-CHLORO-
4 - F L U O R O P H E N Y L ) - 4 - A R Y L - 6 - ( 4 - M E T H O X Y P H E N Y L ) - 3 , 4 -
DIHYDROPYRIMIDIN-2-THIONE-5-CARBOXYLATES.
Dihydroyrimidinthiones have been studied extensively because of their ready
accessibility, diverse chemical reactivity and broad spectrum of biological activities.
Led  by these considerations the synthesis of pyrimidine derivatives of type (VI)
has been undertaken by the cyclocondensation of ethyl-3-(4-methoxyphenyl)-3-
oxopropanoate, N-(3-chloro-4-fluorophenyl)thiourea and aryl aldehydes.
The structure elucidation of synthesized compounds has been done on the
basis of elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay
like antibacterial activity towards gram positive and gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40µg/ml.
The biological activities of synthesized compounds were compared with standard
drugs.
Type(VI)
R=Aryl
NH
N
R
S
F
Cl
O
CH3
O
OCH3
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O
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 Observed
Type     Ref.
        Reported
Frequency in cm-1 Vibration
I R  S P E C T R A L  S T U D I E S  O F  E T H Y L - 1 - ( 3 - C H L O R O - 4 - F L U O R O
P H E N Y L ) - 4 - ( 3 - N I T R O P H E N Y L ) - 6 - ( M E T H O X Y P H E N Y L ) - 3 , 4 -
DIHYDROPYRIMIDIN-2-THIONE-5-CARBOXYLATE.
Alkane C-H str. (asym.) 2935 2975-2950 126
-CH3 C-H str. (sym.) 2844 2880-2860  , ,
C-H i.p.def. (asym.) 1461 1470-1435  , ,
C-H o.o.p. def. (sym.) 1355 1390-1370  , ,
Aromatic C-H  str. 3051 3090-3030 127
C=C str. 1423 1540-1480  , ,
C-H i.p. (def.) 1095 1125-1090  , ,
C-H o.o.p. (def) 808 835-810  , ,
Pyrimidine C=C str. 1560           1580-1520  , ,
   moity           C-H str. 3101 3080-3030  , ,
          C-H i.p. def. 1168 1125-1090  , ,
Amine           -NH str. 3406 3410-3380 126
-NH def. 1649           1635-1595  , ,
Ester - C=O str. 1718           1690-1660           , ,
Halide -C-CI str. 740             700-750  , ,
N
H
N
S
F
Cl
O
CH3
O
O
CH3
NO2
0.0
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cm
 478.3
 515.0
 553.5
 582.5
 621.0
 657.7
 682.8
 704.0
 740.6
 808.1
 846.7
 889.1
 929.6
1018.3
1095.5
1168.8
1199.6
1261.4
1315.4
1355.9
1423.4
1461.9
1510.2
1533.3
1560.3
1596.9
1649.0
1718.5
2844.8
2935.5
3068.5
3101.3
3190.0
3406.1
Mode
Instrument : SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 4000-400 cm-1
(KBr disc.)
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NMR SPECTRAL STUDIES OF ETHYL-1- (3 -CHLORO-4-FLUORO
P H E N Y L ) - 4 - ( 3 - N I T R O P H E N Y L ) - 6 - ( M E T H O X Y P H E N Y L ) - 3 , 4 -
DIHYDROPYRIMIDIN-2-THIONE-5-CARBOXYLATE.
Signal
  No.
Signal Position
    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
1 1.09 3 H triplet -CH3 -
2 3.90 3 H singlet Ar-OCH3 -
3 4.76 2 H quatret -CH2 -
4 5.76 1 H singlet Ar-Hc -
5 7.21-7.24 2 H doublet Ar-Hb,b’ Jaa ’=9.0
6 7.24-8.34 7 H multiplet Ar-H
7 7.97-8.00 2 H doublet Ar-Ha,a’ Jbb ’=9.0
8 10.07 1 H singlet NH(Pyr.) -
NH
N S
F
Cl
O
CH3
O
OCH3
NO2
a
b
c
a'
b'
Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER Spectrometer
(300 MHz)
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF ETHYL-1-(3-CHLORO-
4 - F L U O R O P H E N Y L ) - 4 - A R Y L - 6 - ( 4 - M E T H O X Y P H E N Y L ) - 3 , 4 -
DIHYDROPYRIMIDIN-2-THIONE-5-CARBOXYLATES.
(A) Synthesis of Ethyl-3-(4-methoxyphenyl)-3-oxopropanoate.
See Part-I, Section-II (A).
(B) Synthesis of N-(3-chloro-4-fluorophenyl)thiourea.
See Part-I, Section-IV (A).
(B) Synthesis of Ethyl-1-(3-chloro-4-fluorophenyl)-4-(3-nitrophenyl)-6-(4-
methoxyphenyl)-3,4-dihydropyrimidin-2-thione-5-carboxylate.
A mixture of ethyl-3-(4-methoxyphenyl)-3-oxopropanoate (2.22 gm, 0.01
mol ) ,  N- (3-ch loro-4- f luorophenyl ) th iourea  (2 .04  gm,  0 .01  mol )  and  m-
nitrobenzaldehyde (1.51 gm, 0.01 mol) in 15 ml of ethanol containing few drops of
concentrated hydrochloric acid was refluxed for 24 hrs. The solution was allowed
to stand for 12 hrs. at O
0
C. The resulting solid mass separated was filtered and
crystallized from dioxane. Yield 48%, m.p.273
0
C, Anal.Calcd. for C26H21CIFN3O5S
Calcd: C, 57.62; H, 3.91; N, 7.75%, Found:  C, 57.60; H, 3.90; N, 7.73%.
Similar ly,  other  E thy l -1 - (3 -ch lo ro -4 - f luoropheny l ) -4 -a ry l -6 - (4 -
methoxyphenyl)-3,4-dihydropyrimidin-2-thione-5-carboxylates were prepared. The
physical data are recorded in Table No.12
(C) Biological screening of Ethyl-1-(3-chloro-4-fluorophenyl)-4-aryl-6-(4-
methoxyphenyl)-3,4-dihydropyrimidin-2-thione-5-carboxylates.
Antimicrobial testing were carried out as described in Part-I Section-I(C).
The zones of inhibition of test solutions are recorded in Graphical Chart No.12
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